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Abstract 
In 1995 the United States implemented a single-dose strategy of varicella 
vaccination in infants.  Varicella incidence, morbidity, and mortality declined 
dramatically, though outbreaks continued, even in highly vaccinated populations, and the 
incidence of varicella began rising in 2003.  These events prompted the recommendation 
of a two-dose vaccination strategy in 2005. In part one of this dissertation, a 
deterministic, age-structured transmission model of the two-dose strategy is used and 
predicts a large epidemic of varicella in the near future, even with high second-dose 
coverage rates.  In the long-term, incidence rates under a two-dose regime will be 10% or 
less of the pre-vaccination rates, compared with up to 50% with a continued one-dose 
strategy.  Varicella cases will consist mostly of mild, breakthrough disease in previously 
vaccinated individuals.   
A full sensitivity analysis should be performed on all models of disease 
transmission.  The sensitivity analysis is used to determine the sensitivity of the model 
output to the values of input parameters, and to the structure of the model itself.  In part 
two of this dissertation, we present a simple, systematic method to perform deterministic 
sensitivity analysis on a mathematical model of infection transmission, and apply it to the 
varicella transmission model of part one.  The methods are general, and should be 
applicable to any qualitative transmission model.  
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I. Introduction 
A. The Epidemiology of Chickenpox 
Varicella Zoster Virus (VZV) is the etiologic agent of the diseases varicella, or 
chickenpox, and Herpes Zoster, or shingles.  It is an α-Herpes Virus, and like all Herpes 
viruses, infection is lifelong, and reactivation of latent virus can cause disease long after 
the initial infection.  Varicella is typically a childhood disease, whereas zoster, which is 
reactivation of latent VZV, is a disease of older adults.1 In temperate, developed countries 
without vaccination, VZV infects more than 95% of the population before reaching 
adulthood.2, 3 Chickenpox is commonly perceived as a relatively minor disease of 
childhood.  Before vaccination the incidence of hospitalization was 2 per 100,000 person-
years in children less than 15 years old, with a case-fatality rate of 2 per 100,000 cases.4 
Infection after age 15 is much more severe, with 18 hospitalizations, 15 cases of 
encephalitis, and 50 deaths per 100,000 person-years.5 A more common serious 
manifestation of adult infection is congenital varicella syndrome.6  
Varicella also causes a financial burden.  A 1986 study estimated the annual 
economic impact of varicella at $400 million.  Most of that cost was attributed to parents 
missing work to care for their sick child.7  
 A modified live virus vaccine against varicella was developed in Japan in the 
1970s.8  In 1995, following the results of several randomized controlled vaccine trials, the 
US began mass vaccination of infants between 12 and 15 months.  Currently, vaccination 
coverage is high (~88% nationally).3 Within 10 years, vaccination had reduced the 
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incidence of chickenpox by roughly 80%, with hospitalizations and mortality falling by a 
similar amount.9 However, since 2003 incidence rates have stabilized and even started to 
increase in some areas.10 
 Surveillance data suggest that the effectiveness of the vaccine in a population 
setting has been less than what efficacy trials predicted.11 Breakthrough disease, defined 
as infection in a previously vaccinated individual, continues to occur.  Several well-
publicized outbreaks have occurred in schools and day care centers, with attack rates in 
vaccinated children ranging from 12% to roughly 50%.12-16 Breakthrough disease tends to 
be much milder, indicating that the vaccine is effective against serious morbidity despite 
a low effectiveness in preventing infection.12-14, 17, 18 Due to the occurrence of 
breakthrough disease, a second dose of vaccine is now recommended for all children at 
age 4-6 years in an effort to stop breakthrough disease.  The first dose of vaccine is still 
recommended between 12 and 15 months of age.10,19   
 Several models have explored the epidemiology of varicella following the 
introduction of a routine single dose vaccination strategy and predicted a resurgence of 
incidence within several years of the introduction of the vaccine.11,25 This is not 
surprising as many models, as well as observed data for diseases other than varicella, 
show that there is often a resurgence of incidence within several years of the start of a 
mass vaccination campaign.20-25 While a two-dose program will almost certainly decrease 
the incidence of chickenpox, the extent to which this will happen has not been thoroughly 
evaluated yet.  Additionally, vaccination causes the average age of infection to increase 
and a second dose will increase the age further.3 This may problematic given the increase 
in morbidity that results from infection at an older age, as well as an possible increased 
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risk of congenital varicella syndrome as infection moves into older age groups. 
 
B.  Statement of Purpose 
This dissertation will describe the immediate and long-term epidemiologic effects 
of a two-dose vaccine campaign on the epidemiology of chickenpox.  Close attention will 
be paid to the epidemiology of chickenpox in the next 20 years.  This will be 
accomplished with the use of age structured, deterministic, compartmental mathematical 
transmission models.  These will be specified in such a way as to make general 
predictions about future trends in the incidence of varicella including breakthrough 
varicella.  The model is thus qualitative by nature.  A specific prediction about incidence 
rates or total numbers infected is not a goal of the model.  The model will explore the 
long-term epidemiology of varicella, comparing a continued single dose campaign with 
several variations of a two-dose regimen.  The long- term epidemiology of two-dose 
regimens will be compared to what would have happened if a one-dose recommendation 
had persisted.    
A thorough sensitivity analysis will be performed to assess the range of outcomes 
that are possible given uncertainty about the input values into the model.  Sensitivity 
analyses are crucial for validating models, and determining their generalizability to 
different settings.  Too often, sensitivity analyses are incomplete, and no single standard 
method is utilized throughout the transmission modeling literature.26 A systematic, step-
by-step method for sensitivity analysis will be described.   
 These analyses will aid in public health planning for the future control of 
varicella.  These results could help policy makers determine the best strategies for two-
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dose vaccination.  Additionally, it will show the expected trends in varicella incidence 
over the next two decades, when a resurgent epidemic could be expected.  Such 
qualitative predictions are important for planning public health interventions aimed at 
preparing for and controlling for such an epidemic, if it is expected.  The sensitivity 
analysis will present a picture of possible alternative scenarios that could affect the 
likelihood of a resurgent epidemic, as well as the range of long-term epidemiologic 
effects of two-dose vaccination given some degree of uncertainty about the values for 
input parameters.  From a methodological standpoint, the description of a recommended 
strategy for assessing the sensitivity and uncertainty present in models will aid future 
modelers in their efforts, and increase the generalizability across different models in 
different populations. 
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II. Review of the Literature 
A. The Epidemiology of Varicella Zoster Virus 
1. VZV Infection 
Chickenpox is perceived as a minor childhood disease, yet its public health 
impact is substantial.  Varicella-Zoster Virus (VZV) is the etiologic agent that causes 
both chickenpox (varicella), a disease that occurs in childhood, and Herpes Zoster (HZ, 
zoster, or shingles), a disease that occurs predominantly in adults and 
immunocompromized individuals.  VZV is a herpes virus, and like all herpes viruses 
results in life-long infection.   
The virus is transmitted via infectious droplets originating from vesicular fluid or 
respiratory secretions from infectious hosts.  Infection occurs when these droplets contact 
mucosal surfaces in a susceptible person.  Typically this occurs via inhalation.  After 
roughly four days of replication at the site of infection, a viremia occurs as virus spreads 
to lymph nodes.  After about 1 week of replication in lymph nodes a second, more severe 
viremia occurs as T-cells transport the virus to epidermal cells.1,2 Replication at the skin 
surface results in a process called ballooning degeneration where multinucleate giant 
cells are formed and quickly die.  The characteristic vesicular rash occurs as an exudate 
forms between living and dead cells.3 The incubation period (from infection to rash) lasts 
around 14 days.  Infected individuals become infectious during the last two days of the 
incubation period, typically via respiratory secretions.4  
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The clinical course of chickenpox in an individual typically consists of fever and 
a maculopapular-vesicular rash that lasts about one week.5 Other constitutional symptoms 
include headache, sore throat and fatigue in a prodromal period 1-2 days before the onset 
of the rash. The most serious complications include central nervous system involvement, 
pneumonia, severe bacterial superinfections, and occasionally death.4   
The vast majority of those infected recover within 5 to 7 days, with no sequelae.  
The virus then becomes latent in dorsal root ganglia and ganglia of the trigeminal nerve.  
Virus associated DNA can be found in these nerve cells, as well as in associated cells 
such as glial cells and satellite cells.6 Re-infection is rare, but reactivation causes herpes 
zoster, or shingles.  Herpes Zoster is a significant cause of morbidity in older adults, and 
its incidence plays a role in VZV epidemiology.  Herpes Zoster is currently the focus of 
much research.  The main focus of the research for this dissertation, however, will be on 
chickenpox.  
 
2.  VZV Impact 
In developed countries with a temperate climate and without a routine VZV 
vaccination program, VZV infects more than 95% of the population before reaching 
adulthood.7 Prior to vaccination, the annual incidence rate in the United States was 15-16 
cases per 1,000, resulting in roughly 4 million cases annually.8 The incidence is highly 
age-dependent, with 90% of children infected by age 12.  In the pre-vaccine era, peak 
incidence varicella occurred in 3-6 year olds, with estimated incidence rates of up to 120 
cases per 1,000 person-years.9 
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The nearly 4 million annual cases in the US lead to approximately 9,300 
hospitalizations and 100 deaths.10, 11 Hospitalization rates ranged from 2 to 6 cases per 
100,000 population.12,13, and case-fatality rates ranged from 2-4 per 100,000 varicella 
cases.10, 14 These summary statistics obscure an important facet of the epidemiology of 
varicella morbidity and mortality, namely its severity in adults and infants.  The 
hospitalization rate for varicella in adults aged 20 and older is 13 times that of children in 
the 5 to 9 year age group.12 Among infants <1 year, the hospitalization rate is 6 times that 
of the 5-9 year age group.12 The case fatality rate in adults ranges from 21.3 to 50 deaths 
per 100,000 cases, compared with 2-4 per 100,000 varicella cases in children.15, 16 
Furthermore, it is estimated that 75% of varicella associated deaths in adults occur in 
healthy individuals without pre-existing conditions.17 
In addition to the direct effects of morbidity and mortality, varicella in the pre-
vaccination era was associated with a significant financial burden. A 1986 study 
estimated the annual economic impact of varicella in the US at $400 million.  Most of 
that cost was attributed to parents missing work to care for their sick child.14 An 
Australian study estimated a mean of 5.5 days of missed school or day-care for infected 
children.  While medical costs for each infected child were relatively low ($33 per child), 
the total cost per infected child including work and school absenteeism was estimated at 
$393 to $578 per child.18 In a German study, savings of 4 to 8 Euros were anticipated for 
each euro invested in vaccination.19 A follow-up study estimated that with 85% vaccine 
coverage, the break-even point financially occurs at three years.20 Recent studies in the 
US have estimated that prevention of varicella through vaccination can result in a total 
annual savings of $1.3 billion in direct and indirect costs.15 
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B. Varicella Vaccination 
 1. The VZV Vaccine 
 All VZV vaccines are derived from the same original seed strain.  The Oka strain of 
VZV was isolated from a Japanese child in the early 1970s and attenuated via cell-culture 
passage.21 Japan licensed the first Oka vaccine in 1987 followed by Korea in 1988.22 In 
1995, an Oka strain vaccine, VARIVAX® (Merck & Co., Inc., Whitehouse Station, New 
Jersey), was licensed for use in the United States for children 12 months and older.  It is 
the most commonly administered varicella vaccine.23 Another Oka vaccine, 
Varilix®(GlaxoSmithKline) is licensed for use in children 9 months of age and older.  In 
2005 a combined measles, mumps, rubella and varicella (MMRV) vaccine ProQuad®, 
was licensed for use in children 12 months to 12 years.4   
 Vaccination is recommended for all children at 12 months of age, with catch-up 
vaccination for susceptible children up to 12 years of age, and for susceptible adults 
likely to have contact with infectious persons such as parents with young children, 
schoolteachers, and health care workers.  Vaccination is also recommended before school 
entry, for outbreak control, and for children with HIV.15 A single dose was recommended 
at 12 months, and 2 doses at least 3 months apart for anyone older than 12 years old.  A 
2-dose regimen for all children has been recommended since 2005.  The current 
recommended timing is one dose at 12 months, and a second dose between 4-6 years of 
age.24 Currently, vaccination coverage is 88% nationally4, with a range of 69% to 96% 
depending on region.25 
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 2. Immune Response to Immunization 
 The pathogenesis of infection with the VZV vaccine (Oka strain) is similar to that 
with wild-type virus, but usually without the vesicular rash or constitutional symptoms.1 
Some children may develop a rash within 42 days of vaccination, but the illness is 
typically quite mild.  More serious reactions including anaphylaxis, encephalitis, 
thrombocytopenia and pneumonia have been reported rarely.26 There have been a few 
cases of transmission of the vaccine strain, likely via respiratory spread.1   
 Several studies have evaluated the nature and persistence of the immune response 
to VZV vaccination.  Natural infection and vaccination both stimulate a humoral reaction 
against glycoproteins present on the surface of the virion.27 A glycoprotein ELISA 
(gpELISA) measures antibodies against these glycoproteins.  A titer >=5 units/ml is a 
reliable indicator of immunity.28, 29 At least 85% to greater than 90% of children will 
achieve such a protective titer after one dose of vaccine.30 A large retrospective analysis 
of 5 multi-center clinical trials examined 3,771 children aged 12 to 23 months who had 
pre and post-vaccination VZV antibody titers measured.  Following immunization with 1-
dose of Varivax® vaccine, greater than 90% of children achieved a 6-week post 
vaccination geometric mean titer (GMT) of 13.1 or greater as measured by the 
gpELISA.31 According to studies examining the persistence of anti-VZV antibodies, 
humoral persistence lasts for at least 10 years.30, 32-38 
  By 12 months of age most children mount an effective cellular immune response to 
vaccine and wild-type VZV.  Markers of cellular response such as the stimulation index 
(SI) demonstrate a proliferative T-cell response to vaccination.  Cytokine stimulation also 
occurs.39-41 The cellular response elicited by vaccination persists for several years.33,38,42, 
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43 Some vaccinated children fail to mount a humoral response to vaccination, and can be 
subsequently infected (breakthrough infection).  A decreased duration and severity of 
breakthrough disease demonstrates a cellular response to vaccination.44, 45 
 
 3. Efficacy trials of the VZV vaccine 
 Vaccine efficacy is a function of the proportion of vaccinated individuals who 
acquire any protection, the degree of protection, and the duration of protection.  It is 
measured by the relative risk of infection in vaccinees compared with the unvaccinated.46 
Efficacy is a term typically reserved for the performance of the vaccine under ideal 
conditions, such as clinical trials.  The performance of the vaccine under field conditions, 
or vaccination in the community, is usually referred to as effectiveness.   
 Pre-licensure clinical trials and post-licensure surveillance studies have 
demonstrated the efficacy of this vaccine.  Estimates for protection from any (mild and 
severe) disease are 70% to 100% over 7-10 years when administered at 12 months. 34 
Efficacy against severe disease has been measured at 95%, also over 7-10 years when 
administered at 12 months.36, 37, 47   
 Two double blind, randomized, placebo controlled, clinical trials in healthy 
children were conducted before licensure of VZV vaccine in the US.48, 49 In a trial in the 
US, vaccine was randomly assigned to 956 one to 14 year old children.  The efficacy was 
100% in over 9 months of follow-up, and 98% after 2 years of follow-up.48 A subset of 
vaccinated children was followed for an additional 3 to 7 years.  The study was no longer 
blinded at this point.  After 7 years the efficacy was 95.7%.34 In a European trial, 513 
children aged 10-30 months were followed for 29 months.  Vaccine efficacy was 88.2% 
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over the study period.49 
 Another clinical trial studied 3,303 vaccinees.  A subset of 1,463 subjects was 
randomized to one of 5 production lots of vaccine.  This trial was not placebo controlled. 
Questionnaires regarding illness and blood samples were taken at 6 weeks and 1 year 
following vaccination.  The immunogenicity of the vaccine was similar to that found in 
other studies.  The 6-week seroconversion rate was 96%.  Seropositivity was measured 
by the gpELISA and defined as a 3 standard deviation increase in post-vaccination 
optical density.  After 1 year, 99% of the subjects had positive titers, with a geometric 
mean titer (GMT) between 10 and 15 units/mL, well above the 5 units/mL threshold that 
is correlated with protection.  The efficacy of the vaccine was 86% after 1 year.22   
 
 4. Post-licensure Surveillance 
 The post-licensure effectiveness of the Varivax® vaccine, as measured by 
household contact, case-control, and retrospective cohort studies, averaged 80% to 85% 
against any disease, and 95% against severe disease, estimates consistent with the pre-
licensure data.4, 30 
 The largest and most complete household contact study was conducted between 
1997 and 2001 in Antelope Valley, California.  Active surveillance identified 1,602 
primary cases of varicella and 5,912 household contacts.  The attack rate in vaccinated 
contacts of unvaccinated cases was 15.1%.  This is contrasted with a secondary attack 
rate of 71.5% when both the case and the contact were unvaccinated.  Vaccine 
effectiveness (%) is calculated by the cohort method50: 
[(ARU – ARV)/ARU] x 100 
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where ARU and ARV stand for the secondary attack rate in unvaccinated and vaccinated 
contacts respectively.  In this study the effectiveness of varicella vaccination against any 
disease was estimated at 79%.  It is important to note that household exposures are more 
intense and occur for a longer duration than the typical community exposure.51 
 The success of the single-dose varicella vaccination campaign has also been 
measured by changes in varicella incidence, hospitalization and case fatality rates. Within 
10 years, the incidence of chickenpox has fallen by roughly 80% in most areas, with 
hospitalizations and mortality decreasing by a similar amount.  Data from three sites with 
active varicella surveillance have been instrumental in documenting this trend.   
 In the previously referenced site in California, the annual incidence was 10.3 per 
1,000 population in 1995, just before vaccination began.  Age-specific data were 
consistent with other studies, with rates of 48.8/1,000 for 1-4 year old children, and 
54.9/1,000 among 5-9 year olds.  Seroprevalence data indicated that 93% of the 
population was infected by age 15.52 In 2000, five years after the implementation of 
routine varicella vaccination, and with a vaccine coverage rate of 82.1%, the overall 
varicella incidence rate at the California site was 2.5 cases per 1,000 population, a drop of 
roughly 95%, with significant declines in all age groups.  The highest rates continued to 
occur in the 1-4 and 5-9 year age groups, with rates of 7.5 and 20.5 cases per 1,000 
population respectively. Hospitalization rates also declined ranging from 2.7-4.2 cases 
per 100,000 population in 1995 to 0.6-1.5 per 100,000 population by 2000. Similar 
coverage rates and declines were seen in the two other surveillance sites (West 
Philadelphia, PA, and Travis County, Texas).52 
 A national survey of hospitalization data from 1993 to 2001 revealed a similar 
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decline in varicella related hospitalizations. At the start of vaccination in 1995, the 
hospitalization rate was 5 per 100,000 US population.  It decreased to 2.5 per 100,000 by 
1999, and further fell to 1.3 per 100,000 in 2001.53 The mortality rate attributable to 
varicella decreased from 0.41 per million population at the beginning of vaccination, to 
0.14 per million population by 2001.17 
 
 5. Vaccination and the average age of infection 
 A well-known consequence of vaccination is an increase in the average age of 
infection.54-56 As the incidence rate of an infectious disease increases, the average age at 
infection decreases.  Simply put, if the incidence of varicella is high, individuals spend 
less time susceptible to infection before becoming infected.  This can also be expressed in 
terms of waiting time (wt), where the rate of moving from a susceptible to infected state 
is 1/wt.  With vaccination, incidence rates decrease, and the average age of infection 
increases. 
 This has important implications for VZV vaccination programs.  Recall that 
morbidity and mortality increases substantially when infection occurs after age 15.10,15,16 
While vaccination will decrease the overall incidence of disease, an shift in the average 
age of infection could lead to a net loss of public health.  This concern was widely 
discussed before widespread vaccination started.9, 23 These changes have also occurred 
with rubella, a disease with potentially serious consequences in adolescents compared 
with younger children.57 
 In the absence of vaccination, peak infection rates in temperate, industrialized 
countries occurred in 1-4 year olds, with upwards of 95% of the population infected by 
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age 12.9 In Canada and the UK, highest rates were seen between ages 5 to 11 years.  
However, in the years just preceding the beginning of vaccination, rates increased in 
children aged 2-4 years, presumably as a result of increased day care utilization, and thus 
more contacts in this age group.7 This pre-vaccination shift has occurred elsewhere, with 
the highest incidence shifting from 5-11 year olds to 1-4 year olds in the US.58 
 Modeling studies were utilized to predict the shift in the average age of infection 
that would occur with vaccination.  Models by Halloran et al. predicted more cases in 
individuals 30 years and older after vaccination than before vaccination.  However, when 
infection occurred in individuals partially protected by prior vaccination, the severity of 
disease is likely to be less than infection in completely susceptible individuals.59, 60 
Another model predicted that after vaccination, 81% of cases would occur in children 12 
years of age and younger, compared with 86% before vaccination.  However, this model 
also predicted that with different assumptions about vaccine coverage and population 
mixing, up to 50% of cases could occur in those aged 19 years and older.  The absolute 
number of cases drops in all age groups, so a net loss in public health was not predicted.61 
 With over 10 years of widespread vaccination in the US, data are now available on 
the shift in the age distribution of VZV infection.  The most complete data come from 
active surveillance conducted in Antelope Valley, California, Philadelphia, Pennsylvania, 
and Travis County, Texas.  In these communities, the peak infection rates have shifted 
from 3-6 years of age before vaccination to 9-11 years of age 10 years after vaccination 
started.52 The increase in the age distribution has thus not yet caused the peak incidence 
to shift into age groups where infection is more dangerous, and incidence, morbidity and 
mortality have fallen in all age groups.17 
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C. Breakthrough Varicella 
 While the routine vaccination campaign has been highly successful in reducing 
varicella morbidity and mortality in the US17, 52, 53, the issue of “breakthrough varicella” 
surfaced.  Breakthrough varicella is defined as chickenpox in a vaccinated individual, at 
least 42 days after vaccination (which differentiates it from symptoms of pre-vaccine 
incubating infection, or symptoms caused by vaccination). 5, 52   
 
 1. Morbidity of breakthrough varicella 
 Breakthrough disease tends to be milder than chickenpox in an unvaccinated 
individual.  Afflicted individuals typically have fewer vesicles (<50 is a usual cutoff for 
mild disease), a lower incidence of fever, a shorter duration of disease, and are less 
contagious.4, 5 Breakthrough disease is mild in roughly 75% of breakthrough cases.  The 
remaining 25% of breakthrough cases are severe, have >50 vesicles, and are prone to the 
full effects of chickenpox infection, including contagiousness similar to natural 
infection.15, 62-64 
 A matched case control study identified 202 PCR positive cases and 339 matched 
controls.  Out of 122 previously vaccinated cases, 87% had mild disease with <50 
lesions.  Only 98 (45%) of the unvaccinated cases had mild disease.  The rash in 
unvaccinated cases was also more severe than in vaccinated cases.65, 66 
 One study examined the effect of time since vaccination on the severity of 
breakthrough varicella. Severe disease was defined as chickenpox with >50 lesions.  
Among unvaccinated children, severity of disease increased as the age of disease onset 
increased.  Compared with children infected before 1 year of age, those infected at 8-12 
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years were 1.53 (CI 1.26-1.85) times as likely to have severe disease, and those infected 
at 13 years or greater were 2.2 (CI 1.76-2.24) as likely to have severe disease. 67 
 
 2. Incidence of breakthrough varicella 
 The annual incidence of breakthrough varicella is currently estimated to be 2%-3% 
per year.22, 46  A large randomized trial compared children receiving 1-dose of Varivax® 
with children receiving 2-doses, 3 months apart.30 The trial enrolled 2,216 one to twelve 
year old children between 1991-1993 and followed them for 10 years. The yearly 
incidence proportion in the single dose group ranged from 0.2% to 2.3% with the highest 
incidence occurring 2 to 5 years after vaccination.  The 10-year cumulative incidence was 
7.3% (95% CI 5.5,9.0).  The majority (77.2%) of breakthrough cases were mild, with <50 
vesicles.  Roughly 23% had more than 50 vesicles, with disease similar to natural 
varicella.  Overall, one dose of vaccine was 94% against any disease.   The efficacy was 
98.3% in the two-dose group, with a 10-year cumulative incidence of 2.2% (95% CI, 
1.2,3.2).  Breakthrough disease was mild in 81% of cases.  It is unclear why the incidence 
was highest in the period 2-5 after vaccination.  As wide-scale vaccination started in 
1995, 2 to 4 years after enrollment, it is possible that exposure to wild-type virus was 
limited during this 2-5 year period.  The increased incidence could have resulted from a 
lack of exogenous boosting (exposure to wild-type VZV) rather than decreased vaccine 
effectiveness. 
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 3. Infectiousness of breakthrough cases 
 In a household contact study, the transmission potential of VZV from individuals 
with breakthrough disease to vaccinated and unvaccinated contacts was evaluated. 51  
Attack rates were calculated for transmission from vaccinated and unvaccinated cases to 
vaccinated and unvaccinated contacts.  The transmission rate from unvaccinated cases to 
unvaccinated contacts was 71.5%, consistent with other studies.68 Transmission from 
breakthrough varicella cases to unvaccinated contacts was highly dependent on the 
number of vesicles.  Only 23.4% of unvaccinated contacts of breakthrough cases with 
<50 vesicles became infected, whereas 65.2% became infected when there were >50 
lesions.51 This study confirmed prior observation that children with fewer than 50 
vesicles have milder disease and are less infectious, whereas children with more than 50 
vesicles tend to have more severe disease and a transmission potential similar to that seen 
in unvaccinated individuals.29, 32, 69 
 
 4. Outbreaks of breakthrough varicella 
 Because the duration and intensity of exposure is higher in households than in the 
community at large, estimates of attack rates in households may overestimate the 
secondary attack rates typically seen in the community.51 Several reports have 
documented outbreaks of breakthrough varicella that occurred in schools and day care 
centers, with attack rates in vaccinated children ranging from 12% to 50%.62-64, 70-75 
 In a large case-control study conducted between 1997 and 2003 in Connecticut, 202 
PCR positive cases were compared with 339 matched controls.  Vaccine effectiveness 
against any disease was 87%, and this estimate was unchanged after adjusting for 
 20 
covariates including sex, race, and location of day care, corticosteroid use, asthma, and 
MMR vaccination within 28 days of varicella vaccination.  The effectiveness of the 
vaccine against severe disease was 99%.65 
 One outbreak occurred in a daycare facility in New Hampshire in 2000.63 The index 
case appeared to be a previously vaccinated four-year old boy with severe breakthrough 
varicella (fever and  >150 lesions).   Varicella developed in 25 out of 88 at risk.  
Seventeen of the cases had been previously vaccinated, 8 were not.  The 63 children who 
escaped infection included 10 (15.9%) unvaccinated, 32 (50.8%) vaccinated, 16 (25.4%) 
with previous infection, and 1 with an unknown history.  The secondary attack rates in 
vaccinated and unvaccinated children were 34.6% and 44.41% respectively. Vaccinated 
children experienced milder disease with a shorter duration than unvaccinated children.  
In this population the vaccine effectiveness against any disease was 44% (95% CI 
6.9,66.3), and 86% (95% CI 38.7,96.8) effective against severe disease.76 
 In 2002, another outbreak occurred in an elementary school in Minnesota.  The 
investigation identified 49 infected students who did not have a previous history of 
chickenpox.  The case definition for infection classification was the acute onset of a 
macropapular rash, with no other apparent cause, between July of 2002 and January of 
2003.  Morbidity was defined as mild when <50 lesions were present, moderate at 51-100 
lesions, and severe if >100 lesions were present.  Breakthrough disease was defined as 
varicella illness in a child vaccinated >42 days before symptom onset.  Vaccine coverage 
among the 49 infected was 59% (29 total), 41% (20 total) were not vaccinated.  Overall 
there were 36 unvaccinated children at the school, and 118 vaccinated children.  The 
attack rates were 25% (29/118) in the vaccinated, and 56% (20/36) in the unvaccinated.  
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The vaccine effectiveness against was thus 55% against any disease.  Breakthrough 
disease was mild in 76% (23/28) of 28 breakthrough cases, and moderate among the rest.  
In the unvaccinated students, only 20% had mild disease (4/20), with the rest suffering 
moderate disease.  No severe illness was noted.  The vaccine effectiveness was thus 90% 
against moderate illness.62 
 Another elementary school was reported in Utah.  Cases occurred from October 
2002 until February 2003.  The index case was a vaccinated child who developed 
chickenpox with severe complications.  A total of 74 cases (26 vaccinated children and 
48 unvaccinated) were identified at the index case’s school and one other elementary 
school in the community.  The vaccine effectiveness against any disease was 87%, which 
is well within the range predicted in pre and post-licensure studies.  Even though the 
attack rate in vaccinated children was low (4% in one school and 5% in another) parents 
in this small community were left with the perception that the vaccine was ineffective.  
The fact that 35% of the cases were vaccinated fueled this perception.  Additionally, 12 
parents mistakenly assumed that their children were vaccinated against varicella, but 
were in fact not.72 
 The publicity associated with these outbreaks, combined with a general perception 
of chickenpox as a mild illness, may threaten the continued success of the vaccination 
campaign.  Even when the vaccine performs well, parents may misjudge the 
effectiveness.72 The varicella vaccine is already refused by more parents than any other 
recommended childhood vaccine.77, 78 
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 D.  Factors Associated with Breakthrough Disease 
 Several factors associated with vaccine failure and breakthrough disease in some 
studies include a history of respiratory syncytial virus infection, pneumonia, asthma, 
corticosteroid use, and vaccination within 30 days of receiving the MMR vaccine. 79-81 
 Two factors associated with breakthrough disease have received the most attention.  
First, many studies uncovered an association between younger ages (<15 months) at 
vaccination and future breakthrough disease.64, 65, 71, 72, 79 The second association is time 
since vaccination, with longer time periods associated with an increased risk of 
breakthrough varicella and severity of breakthrough disease.63-65, 67, 72, 79, 82, 83 It is 
important to note that these two findings are not consistently present in every study.  It is 
thus worthwhile to consider the type of study design, outbreak vs. specifically designed 
study, when interpreting such results.  The following sections will examine the evidence 
for and against these the associations with age at vaccination and time since vaccination. 
 
 1. Time since vaccination and age at vaccination 
 Several outbreak studies have assessed the associations between breakthrough 
disease, time since vaccination, and age at vaccination.  In the 2000 chickenpox outbreak 
at a New Hampshire day care center, both age at vaccination and time since vaccination 
were associated with the incidence of breakthrough disease.  Children vaccinated 3 or 
more years before the outbreak were 2.6 (95% CI 1.3,5.3) times as likely to develop 
breakthrough disease as children vaccinated less than 3 years prior.  The median age of 
vaccination was 18.4 months for children with breakthrough disease, and 24.7 months for 
children who remained healthy.76 
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 Similarly, an outbreak in elementary schools in Illinois found that vaccination 
before 15 months of age was associated with a 3.7 (1.1 to 13.1) times increased risk of 
breakthrough disease compared with vaccination after 15 months.  No other associations 
were noted.73  
 In the Minnesota elementary school outbreak, receipt of vaccination before 16 
months doubled the risk of breakthrough disease (RR 2.1, 95% CI 1.1,4.1).  Additionally, 
receipt of vaccination 5 or more years before the outbreak led to a risk for breakthrough 
disease 2.6 (1.3-5.4) times as high as vaccination less than 5 years prior to the outbreak.  
The authors also found that children who experience chronic ear infections were twice as 
likely to have breakthrough disease (RR 1.9, CI 1.0-3.5).79  
 The investigation of the Utah elementary school outbreak also revealed an 
increasing risk of breakthrough infection with decreasing age of vaccination, with 
vaccination at or before 18 months associated with an incidence of breakthrough disease 
2.6 times (95% CI 1.2,5.6) as high as for children vaccinated after 18 months.  Similar to 
the Minnesota outbreak, children vaccinated 5 or more years before the outbreak were 3 
(95% CI 1.4,6.4) times as likely to develop varicella as children vaccinated less than 5 
years before the outbreak.  An additional risk factor identified in this study was the 
incidence of eczema.  Children with a history of eczema were 3.8 (1.8-7.1) times as likely 
as children without eczema to have breakthrough disease.  To assess the effect of age at 
vaccination independently of time since vaccination, the investigators restricted their 
analysis to children vaccinated 5 years or more before the outbreak.  The resulting 
relative risk of 9.3 (1.3-68.9) times for vaccination at or before 18 months vs. after 18 
months is interesting, but the width of the confidence interval shows how imprecise this 
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estimate is.  Of the 65 children vaccinated after 18 months in this sub-group, only 1 had 
breakthrough disease.72 
 An outbreak investigation at a school in Oregon showed that vaccination 5 or more 
years before the outbreak was associated with breakthrough disease (RR 6.7, CI 2.2-
22.9).  The attack rate in children vaccinated at 15 months or younger was 14%, 
essentially identical to the attack rate of 11% in children vaccinated after 15 months.74    
 In a daycare center outbreak in Pennsylvania in 2000, children vaccinated before 14 
months of age were 3.0 (95% CI 0.9-9.9) times as likely as children vaccinated at 14 
months or later to develop breakthrough varicella.  No other risk factors were noted.84  
 These results from these outbreak investigations certainly raise the possibility that 
age at vaccination, or time since vaccination may play a role with breakthrough disease 
incidence.  It is important to note that outbreak studies are small, and thus their estimates 
are imprecise.  Their small size decreases the statistical power for multivariate 
assessment of risk factors.15 Age at vaccination and time since vaccination are necessarily 
correlated with each other.  Most of these outbreaks occurred in the first 5 years after 
universal vaccination, thus children vaccinated at the longest time before an outbreak 
were likely to be younger at vaccination than their similarly aged peers who were 
vaccinated more recently.  Thus these variables confound each other, highlighting the 
necessity for studies designed to undertake multivariate analysis.   
 Non-outbreak studies that aimed to examine multiple risk factors for breakthrough 
varicella, especially the effects of age and timing of vaccination, include case-control, 
follow-up, retrospective cohort, and laboratory studies. 
 A large case-control study conducted in Connecticut between 1997 and 2003 
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examined potential risk factors for breakthrough disease.  The analysis was restricted to 
202 PCR confirmed cases and 389 matched controls.  The vaccine was 85% (CI 78-90) 
effective against any disease, and 97% (93-99) against moderate to severe disease, similar 
to other studies.66 In their investigation of risk factors associated with breakthrough 
disease, they found that overall effectiveness was 97% (95% CI 91,99) in the first year 
following vaccination and decreased significantly to a range of 81% to 86% in years 2 
through 8 post-vaccination. Age at vaccination was associated with effectiveness in the 
first year after vaccination.  In the first year following vaccination, the effectiveness of 
the vaccine was 73% in children who received the vaccine before 15 months of age in the 
first year following vaccination, and 99% in those vaccinated at 15 months of age or 
older.  Age at vaccination was not statistically significantly related to vaccine 
effectiveness for years 2 through 8 following vaccination, with effectiveness estimates of 
81% and 85% among children vaccinated before and after 15 months respectively.65 A 
possible explanation for the association of age at vaccination and risk of breakthrough 
disease occurring only in the first year post-vaccination could be the possibility that in the 
first year, most children with poor vaccine response became infected.  Children who were 
vaccinated before 15 months but escaped infection in the first year could have had a 
similar immune response to children vaccinated after 15 months.  The overall decrease in 
effectiveness after year one could indicate that waning immunity increases the risk of 
breakthrough disease over time.  However, the differences in effectiveness were not 
statistically significantly different for years two through eight.  It is important to note that 
this study looked at cases from 1997 to 2003.  Over that time period, vaccine coverage in 
active surveillance sites described previously rose from <20% to >70%.52 Thus, in each 
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year after vaccination, vaccinated individuals had less exposure to wild VZV and 
therefore a lower risk of developing breakthrough disease.  Even if substantial waning of 
immunity was taking place, the increasing risk from waning immunity could have been 
balanced by the decreased exposure. 
 Chavez et al. performed active surveillance in California between 1995 and 2004.67 
Multivariate analysis was performed to examine the risk of breakthrough disease, 
accounting for the independent effects of age at vaccination and time since vaccination.  
One analysis was performed on a subset of children aged 8-12 years, to account for the 
collinearity of age of onset, age at vaccination, and time since vaccination with regards to 
disease severity.  The adjusted odds ratio for the effect of vaccination 5 or more years in 
the past compared with less than 5 years was 2.6 (CI 1.2-5.8).  The rates of breakthrough 
disease increased as time since vaccination increased.  At 1-year post-vaccination, the 
incidence rate was 1.6 (1.2-2.0) per 1,000 person years, increasing to 9.0 (6.9-11.7) per 
1,000 person years at 5 years, 20.4 (14.1-29.6) per 1,000 person years at 8 years, and 58.2 
(36.0-94.0) per 1,000 person years at 9 years.67  This study provides evidence for an 
effect of time since vaccination on the risk of breakthrough disease.  The authors 
conclude that there is waning of immunity over time, but also point out that increasing 
vaccine coverage might have decreased opportunities for exogenous boosting, leading to 
a reduction in vaccine effectiveness over time.  Unfortunately, the investigators did not 
include vaccine coverage as a covariate in their regression model.  Additionally, age at 
vaccination was examined as a categorical variable, and it was not possible to examine an 
independent effect of age at vaccination.   
 Risk factors for breakthrough disease were also identified in a retrospective cohort 
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study at two sites that followed children born after 1993 until 1999.81 In an adjusted 
model, the relative risk for developing breakthrough disease among children vaccinated 
before 15 months of age vs. vaccination at or after 15 months was 1.2 (95% CI 0.8,1.9) to 
1.4 (95% CI 1.1,1.9).  Children who received the varicella vaccine within 28 days of 
receiving the MMR vaccine were 2.1 (95% CI 0.3,16.3) to 3.1 (95% CI 1.5,6.4) times as 
likely to develop breakthrough disease.  Their model adjusted for the effect of time since 
vaccination.  Children who had taken oral steroids were 2.4 (95% CI 1.3,4.4) to 2.8 (95% 
CI 1.0,7.8) times as likely to develop breakthrough disease in the following 3 months as 
children who did not take oral steroids.  Previous studies have demonstrated an increased 
risk of severe varicella among unvaccinated children receiving steroids85, 86, as well as in 
children with severe immunosuppression.87 The authors point out that children who use 
steroids may have more severe breakthrough disease and thus may be more likely to be 
seen at their health maintenance organization, leading to an overestimate of an increase in 
breakthrough incidence in such children. 
 Li et al. performed a prospective cohort study that followed 1,164 children 
vaccinated with a single dose of vaccine between 1991 and 1993, with subsequent 
follow-up for seven years.  Children vaccinated between 1-2 years of age had a 7-year 
cumulative incidence of breakthrough disease of approximately 11%, compared with a 
5% cumulative incidence in children vaccinated between 3 and 5 years of age.88 
Unfortunately, the 1-2 year age group was not split into subgroups that would allow the 
analysis of vaccination at 12-15 months of age vs. after 15 months.  
 The observed association between time since vaccination and breakthrough disease 
can be attributed to several biologically plausible pathways, including waning of vaccine-
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induced immunity, maternal antibody interference with vaccination, immunological 
immaturity, and sub-optimal immune response to vaccination.   
 
 2. Waning of vaccine-induced immunity  
 Humoral immunity is important for protection against VZV infection.  Antibody 
titers <=8u/mL 6 weeks post-vaccination as measured by the fluorescent antibody to 
membrane antigen test (FAMA) led to a 300% increase in breakthrough disease incidence 
compared with a 6-week titer >=64u/mL. Similarly, a 6-week gpELISA <5 u/mL was 
associated with a 250% increase in risk.35, 88, 89 Over time, antibody levels may drop or 
cellular immunity could wane. Sufficient numbers of T and B-cells may be stimulated 
such that the immune system is primed for an anamnestic response upon revaccination or 
natural exposure. However, in the absence of such exposure, populations of virus-specific 
cells decline as a part of normal immune system regulation.44 After a single dose of 
vaccine, the number of helper T-cells and memory B-cells my be insufficient to provide 
long-term protection.  
 
 3. Interference from maternal antibodies and immunological immaturity 
 Antibodies passively transferred transplacentally from mother to fetus can bind to 
vaccine virus, preventing it from being presented to the infant’s immune system. 
Maternal antibody interference led to increasing the recommended age at vaccination for 
measles from 9 months at licensure, to 15 months.  The age was then decreased to 12 
months in 1994 as levels of circulating maternal antibody had decreased after 31 years of 
vaccination.90 This effect has also been described after vaccination against pertussis, 
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influenza, polio, measles, mumps, Haemophilus influenzae b, and many more viral, 
bacterial and protozoan agents.91 In addition to maternal antibody interference, the infant 
immune system may not be sufficiently developed to mount an effective humoral or 
cellular response. 
 
 4. Sub-optimal immune response to vaccination 
A recent population-based study utilized the fluorescent membrane antigen 
(FAMA) test, which is much more sensitive and specific than the widely used 
glycoprotein ELISA (gpELISA), and found that only 76% of vaccinees seroconverted, 
indicating that primary failure or suboptimal vaccine response due to a weak humoral 
response may be more frequent than previously believed based on studies using the 
gpELISA assay.92, 120  
 A review of a large randomized control trial lasting 2 years with an additional 7 
years of follow-up after the trial ended measured antibody persistence in children 
receiving either one or two doses of Varivax®.34, 48  Antibody persistence over time was 
measured using a glycoprotein ELISA (gpELISA).  A titer >=5 units/ml is strongly 
correlated with protection against infection.28, 29 The percentage of vaccinees with a 
gpELISA >=5 units/ml increased from 85.7% to 95.5% by year 5.  The increase in 
seroprevalence could be explained by exogenous boosting from exposure to circulating 
virus, or from endogenous reactivation of the vaccine virus.30 The persistence of anti-
VZV antibody remained stable in years 4 through 10 of follow-up, which corresponds to 
the implementation of universal vaccination.  Vaccine coverage increased from 26% to 
76% during this 6-year period.  If the increasing titers in the first 5 years resulted from 
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exogenous boosting, then the decreasing levels of circulating virus as vaccination 
coverage increased could explain the steady seroprevalence between years 4 and 10.  
While it is difficult to draw definitive conclusions from these results, this study does not 
lend support to the idea that humoral immunity wanes over time.30 
 Another study looked at the persistence of immunity in healthy adults who were 
vaccinated during vaccine trials between 1979 and 1999.  As time since vaccination 
increased, there was no change in the severity or incidence of breakthrough disease. 
Among vaccinees who did not seroconvert, or had lost detectable antibody, breakthrough 
disease was still mild.  This indicates an important and persistent effect of cell-mediated 
immunity.45   
 Health care workers were vaccinated and followed for an average of 4.6 years (1 
month to 20.6 years).  There was no increase in breakthrough incidence or severity over 
time.  The FAMA test, considered the gold standard for antibody detection, was used to 
measure antibody titers.  Five people did not seroconvert after vaccination, three of 
whom became infected.  Of the remaining 115 who did seroconvert after vaccination, 
only 9 (8%) had breakthrough disease.  Thirty-six of the 115 (31%) who did seroconvert 
lost detectable antibody over 1 to 11 years.  Six of these 36 (17%) developed 
breakthrough disease.  Titers were also measured over time to examine antibody 
persistence.  These measurements occurred at <6 months, 6-48 months, and >49 months 
after vaccination.  The proportions with measurable antibody were 93%, 75%, and 86% 
respectively.  Because this study was carried out between 1979 and 1998, it is difficult to 
conclude that humoral immunity was persistent or if exogenous boosting from circulating 
wild VZV was occurring.  The increased breakthrough incidence in seroconverters who 
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became negative over time could indicate waning of immunity.92   
 In a 7-year follow-up study of children who were vaccinated between 1991 and 
1993, nearly 100% seroconverted (>=0.6 u/mL from gpELISA), and the geometric mean 
titer (GMT) increased from an average of 20.3 u/mL (95% CI 18.2, 22.6) after 1 year to 
47.4 u/mL (95% CI 41.2, 55.2) after 6 years.  In addition, breakthrough disease was mild 
and did not change in severity over time.32 
 Taken together, these studies do not indicate that humoral or cellular immunity 
wanes over time.  However, the studies that specifically examined persistence of 
immunity were primarily conducted before there was universal vaccination.  Since there 
was considerable circulating VZV during this period, it is difficult to determine if 
immunity was truly persistent or if there was a boosting effect from exposure to wild 
VZV.  The outbreak studies that demonstrated an association between time since 
vaccination and breakthrough disease incidence occurred in the era of universal 
vaccination, when exposure to wild VZV was decreasing.  These results demonstrate that 
it is difficult to conclude if the increased breakthrough incidence observed as the time 
since vaccination increases is a result of a protective response that wanes over time, or a 
sub-optimal response to a single dose of vaccine that increases susceptibility when 
boosting does not occur. 
 The following studies examine aspects of infant immunity that could explain the 
relationship between age of infection and breakthrough disease incidence.  Results from 
the measles literature are illustrative of the effect of maternal antibody presence and 
vaccination.  A German study found a slightly decreased immune response to measles 
vaccine (measured by prevalence of a humoral response) in 9-11 months olds (84%), vs. 
 32 
older ages (100%).93  A study by Gans et al. was able to evaluate humoral and cell-
mediated immune responses to measles vaccine in the first year of life.  One striking 
finding was that cell-mediated immunity, measured by T-cell proliferation and IFN-
gamma concentrations, did not differ in children vaccinated at 6, 9, or 12 months.  This 
finding did not differ between children who still had passive antibodies vs. those who did 
not.  This would suggest that, at least for measles, immaturity of the cellular immune 
response is not a problem, even at very young ages, and that maternal antibodies do not 
interfere with the cellular immune response.  The humoral response was mitigated in the 
presence of maternal antibodies.  Nine-month olds with measureable maternal antibodies 
did not mount an effective humoral response to measles immunization.  However, 9-
month olds without passive immunity mounted an equally vigorous response as older 
children who also were free of passive antibodies.  Thus the barrier to vaccination, at 
least in 9-month olds, was not a result of cell-mediated immaturity, but simply the 
presence of maternal antibodies.  In 6-months olds, there was evidence of an undeveloped 
B-cell induced humoral response.  Six-month olds were not able to mount a humoral 
immune response to the measles or mumps vaccine, regardless of their passive antibody 
titers.94 
 Maternal antibody interference with varicella vaccination has been investigated.  
Before widespread vaccination, most infants were born with maternal antibodies against 
VZV.  One study found anti-VZV antibodies in more than 96% of cord blood samples.95 
This value is similar to the seroprevalence of anti-VZV antibodies among adults.96-99  
Passive antibody transfer of anti-VZV antibodies to infants via breast feeding does not 
occur.100 
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 Maternal antibodies against VZV have been measured in children up to 15-months 
of age. 28 A Swiss study examined the seroprevalence of anti-VZV antibodies in 
hospitalized infants up to 16 months of age.  Ninety percent of 0-3 month olds, 38% of 3-
6 month olds, and 0% of 6-12 months olds had measurable passive antibody titers.  The 
seroprevalence in children 12-16 months of age was 7%, presumably from exposure to 
circulating virus.101 The same investigators documented a similar decline in maternal 
antibody persistence to varicella, measles, mumps and rubella in a study of pre-term vs. 
full-term infants.102   
 In a large, retrospective analysis of 5 multi-center clinical trials, Silber et al. 
provide evidence against maternal antibody interference with vacccination.31 Their 
analysis included 3,771 children aged 12 to 23 months who had pre and post vaccination 
VZV antibody titers measured.  Seropositivity at 12 months was 27.5%, dropping to 
12.4% at 15 months.  Following immunization with 1-dose of Varivax® vaccine, greater 
than 90% of children achieved a 6-week post vaccination geometric mean titer (GMT) of 
13.1 or greater.  These titers were determined with the gpELISA.  This average result was 
similar to age-stratified results with strata of 12-14, 15-17, and 18-23 months.  The 
authors also looked at immune reactivity in strata defined by pre-vaccination serostatus at 
age 12-14 months.  Among 2,388 children seronegative at this age, 93.6% (92.5-94.5) 
had a gpELISA titer >=5, with a GMT of 15.2 (95% CI 14.7,15.7) 6-weeks after 
vaccination.  For 558 children with low titers (<1.25) of passive antibody at 12-14 
months, 95% (95% CI 92.8,96.6) had a 6-week titer >=5, with a GMT of 14.2 (95% CI 
13.3,15.2).  Finally, for 187 children with pre-vaccination, passive titers >1.25, 93.6% 
(95% CI 89.1,96.6) seroconverted by 6-weeks after vaccination, with a GMT 16.5 (95% 
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CI 13.9,19.6).31 
 These results suggest, similar to what has been observed with measles94, that   
maternal antibody interference is not a factor in children vaccinated after 12 months of 
age.  They provide evidence that maternal antibody presence is minimal at this age, and 
that even when present, does not inhibit the humoral response to the vaccine.  Studies of 
cellular immunity reveal that by 12 months of age the cellular immune response is well 
developed, and that vaccination yields a long-term cellular response.38, 42, 43  
 
 E. Two-Dose Vaccination 
 Regardless of the precise mechanism that leads to susceptibility for breakthrough 
infection, a second dose of vaccine is now recommended for all children between 4 and 6 
years old.15, 24 A second dose of vaccine should cover those who are susceptible to 
breakthrough infection, including those not vaccinated at 1 year, those who had primary 
vaccine failure or sub-optimal vaccine response, and those in whom vaccine induced 
immunity may have waned.44 It is thus hoped that a second dose will prevent further 
outbreaks in highly vaccinated elementary school populations.  
 
 1. Immunologic response to a second dose 
 Several investigations have documented the immunological response to a second 
dose of varicella vaccine.  Humoral and cellular immunity are both greatly enhanced after 
a second dose of vaccine is administered.  Studies that have evaluated cellular immunity 
via the stimulation index (SI) have shown a significant effect after a second dose of 
vaccine.15, 41, 43 A clinical trial in the early 1990s assessed the immune response to two 
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doses of varicella vaccine.  Four hundred and nineteen children who had been vaccinated 
4-6 years previously were given a second dose of vaccine.  Before the second dose, 99% 
of the children were seropositive, the GMT from the gpELISA was 25.7, and the 
stimulation index (SI), a measure of T-cell function, was 40.3.  Three months after the 
second dose, all of the 358 children had antibodies against VZV, with a GMT of 119.0, 
and a SI of 61.4.  This demonstrates the ability for a strong anamnestic response in 
previously vaccinated children.38, 42 A limitation to the study is that children eligible to 
receive the booster dose were those who did not develop breakthrough disease between 
their first dose and 4-6 years later.  Thus, this was a subset of children who had mounted 
a protective response to the first dose of vaccine. 
   A randomized control trial with 10 years of additional post-trial follow-up 
examined 1,029 children randomized to receive two doses given 3-months apart.  All of 
the children developed gpELISA titers >5 u/mL.  The GMT in 2-dose recipients at 6-
weeks post immunization was 142.6 vs. 12.5 for the 1-dose vaccinees.  It should be noted 
that during the 10 years of follow-up, the GMT in the 1-dose group increased to 57.8 
u/mL.  In the two dose group, the GMT dropped to a low of 24.6 u/mL 2 years after 
vaccination, and then rose to 61.0 u/mL by the end of follow-up.30   
 
 2. Second dose efficacy 
 In the randomized control trial just described, individuals receiving one dose were 
3.3 times as likely as those getting two doses to develop breakthrough disease, despite 
similar antibody titers in the two groups.  The cumulative incidence was 2.4% in the two-
dose group compared with 7.3% among the single dose vaccinees.  The estimated 
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effectiveness was 94.4% (95% CI 92.9,95.7) for one dose, and 98.3% (95% CI 97.3,99) 
for two doses.  Among laboratory confirmed cases, the single dose efficacy was 97.8% 
(95% CI 96.7,98.5), with a two-dose efficacy of 99.4% (95% CI 98.7,99.8).  Two doses 
were 100% effective against severe disease.30   
 
 F. Infectious Disease Modeling 
 1. Modeling basics 
 Mathematical models are useful tools for forming hypotheses about how various 
host, population, environmental, and agent specific factors interact to affect infection 
transmission.  They are used to predict outcomes of epidemics, and to assess the likely 
impact of different control measures.  Strengths of the modeling approach are the 
transparent presentation of the model structure, parameter estimation, and various 
assumptions about factors important to infection transmission.   
The simplest types of models are deterministic compartmental models.  These 
models account for the states of the population that are relevant to transmission 
dynamics.  For instance the compartments could represent Susceptibles, Infectious, and 
Recovered and permanently immune (SIR).  Within each compartment, the population is 
treated as a continuous quantity.  The transition, or flow, between compartments is 
modeled using ordinary differential equations that incorporate various epidemiologically 
significant parameters.  The movement from S  I is governed by the “force of 
infection”(λ).  The force of infection is an instantaneous rate at which susceptible 
individuals become infected.  It depends on the rate of contact between an S and I 
individual, multiplied by the probability of transmission when such contact occurs.  The 
Greek letter β represents the transmission contact and transmission rate.  λ is calculated 
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as βI/N where N is the population size.  The incidence rate of infection in the population 
is therefore λS.  Movement from I  R can be expressed as the reciprocal of the 
infectious period, which gives the per-time unit rate of recovery.  The state and dynamics 
of the model can be completely described by a set of differential equations56   
 An important concept in modeling is represented by the basic reproductive 
number, Ro.  Ro is simply the number of new infections that occur if a single infectious 
individual is introduced into a completely susceptible population.  This measure defines a 
threshold value for the occurrence of epidemics.  When Ro>1, an epidemic will occur, if 
<1, the infection will go extinct, and at 1 the disease will remain endemic.  In the SIR 
model described above, Ro is calculated as β/γ, where γ is the recovery rate.56 
 A notable assumption in these simple models is that the population is well mixed or 
homogenously mixed.  A mass action law, derived from the mass action principle that 
describes the rate of chemical reactions in a well-mixed flask, characterizes the incidence 
rate.  Contact is equally likely between any two people in the population.  The probability 
that a susceptible individual has contact with an infectious individual is equal to the 
proportion of infectious individuals in the population.  This assumption is clearly not 
realistic, however for some infectious processes, adding complexity obscures the methods 
without having a meaningful impact on the results.56    
 Many infectious disease models require some amount of heterogeneity in the 
population mixing patterns.  In the case of varicella, mixing rates between different age 
groups have a large impact on the transmission dynamics.  So an age-structured model 
should be used.  Within each age group the model may look like a simple, homogenously 
mixed SIR type model, but there is age dependent mixing between groups.  This 
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heterogeneous age mixing can be accounted for in the force of infection by setting 
different contact rates between different age groups.55, 56, 103   
 A matrix can be constructed showing the contact probabilities between the age 
groups.  This is known as a who acquires infection from whom (WAIFW) matrix.  
Different sorts of mixing assumptions can be made.  In assortative mixing, the majority 
of contacts occur within age groups.  So an infectious 5-year old has the highest 
probability of contacting and infecting another 5-year old.  Disassortative mixing 
assumes that higher contact rates occur between age groups.  In this case the 5 year old 
may infect a 25 year old with a higher probability than any other age group.  With 
proportionate mixing, transmission between groups is proportional to the numbers of 
susceptibles and infectious in each age group.56    
 These matrices can be constructed by observing actual contact rates in a population.  
Or, the age specific incidence rates can be measured, and maximum likelihood techniques 
can describe matrices that would produce such rates.  Such data can yield several equally 
likely matrices.  Thus, subject matter knowledge, and analysis of the sensitivity of the 
output to small changes in the matrix, is needed to choose the best matrix.56, 61 
 
 2. Modeling the transmission of VZV 
 Several studies have modeled VZV transmission.  Most of these studies are 
concerned with the effect of vaccination on the long-term epidemiology.  Factors such as 
changes in the age distribution of infection, reduction in case numbers, reductions in 
morbidity and mortality, and the economic effects of vaccination have all been 
investigated.  The effect of vaccination on herpes zoster (HZ) incidence has also 
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generated substantial interest from the modeling community.  
 Garnett and Grenfell introduced a quantitative model with the aim of describing 
VZV transmission dynamics as well as HZ.  Their model is a simple compartmental, 
deterministic model.  Infants enter the model into a class with maternal antibodies (M), 
become susceptible (S), then exposed (E), infectious (I), and finally recover with 
permanent immunity (R).  In the terminology presented above, this is an MSEIR model.  
The parameters that describe the flow from one compartment to the next are estimated 
from observed data.  Age structure and the rate of zoster occurrence among the recovered 
add complexity to the model.  The effect of age is accounted for by including age-specific 
forces of infection calculated with WAIFW matrix.  Their results concern rates of viral 
reactivation, which causes HZ in previously infected and recovered individuals.  They 
find that an age-dependent reactivation rate approximates real data better than a constant 
reactivation rate.104     
 The above study was not intended to study the effect of vaccination on varicella 
epidemiology.  It is useful to this discussion however, to see how such a simple model is 
used.  Only seven compartments and six partial differential equations were needed to 
describe the infection dynamics in a population.  Despite the simplicity, the authors were 
able to fit a model that produced estimates of HZ incidence that matched real world data.  
 Ferguson et al. used a stochastic, age-structured model to measure transmission 
dynamics following vaccination.  The stochastic model utilizes parameter distributions 
rather than fixed values for the parameters.  Random values from these distributions are 
determined for each run of the model.  The average behavior of the model over repeat 
runs approaches the results of the deterministic model.  By varying parameter values it is 
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possible to quantify a range of possible epidemiologic outcomes. This study was mostly 
concerned with the technical aspects of their model, rather than a study for an audience of 
epidemiologists.  However, they made important findings.  They conclude that after 
vaccination there will be a marked decrease in incidence of VZV, followed years later 
with a large epidemic as the susceptible population accumulates.105 
 Two transmission models published by Halloran in 1996 were the first to study the 
impact of vaccination on breakthrough disease and varicella epidemiology.  One purpose 
of the model was to study the direct effects of vaccination, meaning the effect of 
vaccination in the vaccinated.  Another purpose was to measure the indirect effects, i.e. 
the effect of vaccination in the unvaccinated.  As mentioned previously, vaccination will 
increase the average age of infection.  This occurs in the vaccinated and unvaccinated.  A 
major concern is a marked increase in varicella infection in adults, who are much more 
susceptible to major complications and mortality.  The model was a deterministic, age-
structured, compartmental, model.  Vaccinated children either become completely (but 
not permanently) protected, partially protected (and thus susceptible to breakthrough 
infection) or they stay completely susceptible (primary vaccine failure).  Immunity from 
vaccination wanes at a fixed rate.  If exposed to wild type VZV, the completely protected 
and partially protected can become permanently immune (exogenous boosting).  
Breakthrough disease is another potential outcome when partially protected individuals 
are exposed.  They are infectious but to a lesser degree than unvaccinated infectious 
individuals.  A WAIFW matrix was used to determine contact rates between age classes.  
 Using published values for infectiousness, duration of infection, probability of 
breakthrough disease, and infectiousness of breakthrough cases, the model was 
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parameterized.  Various vaccination assumptions were tested.  These concerned the 
effectiveness of the vaccine, waning of immunity, the amount of protection conferred by 
the vaccine, and vaccine coverage.  For values that were not previously estimated in other 
studies, a panel of 6 experts was used to provide reasonable upper and lower bounds for 
these parameters.  
 The results of the study showed a marked decrease in cases and hospitalizations, 
and a shift towards older age of infection.  Breakthrough disease occurred, but never to 
levels comparable to pre-vaccination varicella incidence.  The age shift did not push the 
average age so high as to increase overall morbidity.  These results were robust to a broad 
range of parameter values.  The important point is made that trends and qualitative results 
of the model are more important than the actual numerical output.59, 60 This model, 
including parameter values and age structure has been used by many other investigators 
to predict the effect of vaccination in different countries and under different 
scenarios.106,107  
 After 5 years of routine vaccination, enough data on vaccine effectiveness was 
available to update the model.46   Brisson et al. observed data on breakthrough disease 
incidence to describe new parameters.  Under their scheme, most individuals move into a 
“vaccinated protected” (VP) class, and some to a “vaccinated susceptible” (VS) class 
following one dose of vaccination.  Upon exposure to wild VZV, most VP become 
permanently immune (R), whereas most VS become infected (breakthrough disease) with 
the remainder moving to VP.  Finally, in the absence of exposure, VP moves so VS at a 
constant rate representing waning immunity.  Their analysis of available data showed that 
previous models underestimated the rate of breakthrough disease significantly.  This 
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model was important in that it updated the values of the parameters determining vaccine 
effectiveness, but was limited as they made the simplifying assumption of homogenous 
mixing and used a model without age structure.46   
 In a later study, this same group used an age-structured model and assessed 
different vaccination strategies.61 The age structure is represented in a WAIFW matrix 
consisting of contact rates estimated by maximum likelihood techniques from data on 
age-specific incidence of natural VZV infection in Canada.  Eight age groups represent 
typical ages for infants, day care users, elementary school children, adolescents, young 
adults, adults, middle age, and elderly.  They also estimate the effect of vaccination on 
HZ incidence.  In one of their models, the contribution of HZ cases to the force of 
infection in susceptibles is constant.  In a second model, they explicitly modeled the 
number of HZ cases, their contact with susceptibles of all ages, and the probability that 
they transmit infection with such contact.  This more complex model did not produce 
significantly different outcomes than the simpler model, so this discussion will be limited 
to the simpler model.  To model demographics, there was a constant birth rate into a class 
protected by maternal antibodies for 6 months who then become susceptible.  The 
maternal antibody class has no relationship with vaccine effectiveness.  Mortality occurs 
only in the 65 years of age and older group.  A constant death rate leads to a life 
expectancy of 75 years, and births balance deaths.61 The infectiousness of breakthrough 
cases was determined from a household contact study.51 
 Their base model assumes 90% vaccine coverage of 12 month olds, a waning rate 
of 0.031 per year (32 year average duration of immunity), with 93% of vaccinees moving 
into VP, 91% of whom become permanently immune with exposure, 73% of VS 
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becoming breakthrough cases with exposure, and breakthrough cases are half as 
infectious as natural cases.  The output of this model shows a 70% drop in varicella in the 
first 5 years after vaccination, somewhat less than the observed 80% decline.52 Their 
model predicts an outbreak 5 years after the start of vaccination, constant breakthrough 
rates, and further predicts that incidence rates will fall to less than 5% of pre-vaccination 
rates after this “post honeymoon” outbreak.15, 44, 52, 108 It is important to note that not all of 
their models predicted the post honeymoon outbreaks, and this was usually dependent on 
the mixing matrix.61 Their output next shows a large increase in incidence from about 12 
to 18 years following vaccination, after which the incidence settles close to an endemic 
equilibrium with rates roughly 15% of what they were before vaccination.  These 
incidence rates include both breakthrough and natural varicella.61  
 It is 13 years since universal vaccination started.  Currently, there are no modeling 
studies predicting the outcome of a second dose for varicella vaccination.  Additionally, 
thorough sensitivity analyses have not been performed in prior studies.  This dissertation 
will attempt to address such questions. 
 
 G. Sensitivity Analysis 
 An important part of any model of infectious disease transmission is the sensitivity 
analysis.  Sensitivity analysis provides information about how uncertainty in model 
structure, assumptions and parameter values affect the outcome.  It allows readers to 
assess the generalizability of the results, which may be limited as parameters are often 
chosen from specific populations.  Even if a modeler has estimated and specified the 
model with a great degree of certainty, the non-linearity that is a hallmark of most 
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transmission models can make predetermination of how parameter variability will affect 
the outcome of interest.   
 Uncertainty may arise for different reasons.  There could be uncertainty about the 
value of inputs, there may be inconsistency about the value or distributional form of a 
parameter in the literature, there could be statistical uncertainty resulting from sampling 
variability, or estimates may have been drawn from different populations.109 Uncertainty 
may be present in the model structure, or the model parameters.  Uncertainty in the model 
structure includes doubt about how parameters should be combined to define processes in 
the model.  Additionally, decisions are made about what factors should or should not be 
included in the model.  Uncertainty about the parameters typically reflects unknown 
estimates, variance, or distribution of values for a parameter.110 Relationships between 
parameters, such as whether the effects are additive or multiplicative provides another 
source of uncertainty about the form of the model.109 Another useful description of the 
sources and issues related to uncertainty come from Briggs et al., who invoke four broad 
types of uncertainty, (1) sampling variability when estimating parameters; (2) 
methodology of estimation; (3) increasing uncertainty about the reliability of parameter 
values over time; and (4) the generalizability of results between populations.111,112 
 The sensitivity analysis should include those parameters for which there is 
considerable uncertainty, or parameters that have been estimated with some certainty but 
have a large influence on the outcome of interest.  Parameters may also have been 
estimated similarly across different studies, but have a wide variance.109 
 There is no standard method to conduct sensitivity analyses in transmission 
modeling studies.   Methods can be qualitative or quantitative, deterministic or 
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probabilistic, and univariate or multivariate.  The purpose of the transmission model 
should dictate whether qualitative or quantitative sensitivity analysis techniques are used. 
Models that make general predictions or analyze trends are well served by qualitative 
sensitivity analysis, whereas models intended to make precise quantitative predictions 
call for a quantitative sensitivity analysis.  
 The simplest and most common type of sensitivity analysis is a one-way, or 
univariate analysis.  In such an analysis, the values of a single parameter are varied from 
some base case; the change in the outcome measure from the base case is calculated, and 
the sensitivity of the output to this single parameter change is investigated.  Typically, 
this is a deterministic method for sensitivity analysis; the modeler directly chooses the 
values for the alternate cases.  In contrast, values are chosen from parameter distributions 
with various sampling schemes in a probabilistic analysis.  
 A recent infection model investigated the differences in mortality from Anthrax 
infection (the model outcome measure) as parameters in the model were varied.  Each 
parameter was changed in isolation, and the percent reduction in mortality for this change 
in the parameter value was measured.  This process was repeated for each parameter in 
the model.  They found that the model was most sensitive to antibiotic efficacy, and was 
only marginally sensitive to antibiotic adherence.  More importantly, the authors were 
able to determine which parameters needed to be specified with greater accuracy and 
precision for future studies.113 
 A model evaluating the effect of recommending an earlier age for influenza vaccine 
among adults used a deterministic, univariate analysis to determine the parameters that 
lead to the greatest uncertainty in the model outcome, which was the cost associated with 
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a vaccination policy where all vaccinees were reimbursed, vs. the current policy where 
only high risk adults are reimbursed for vaccination.  The study determined that the 
choice of policies was not as important as the incidence rate of influenza, proportion of 
the population at high risk, and the mortality rate.114 
 These simple sensitivity analyses provide important insights into the factors that 
affect the chosen outcome for a transmission model.  They help determine which 
parameters need to be estimated with greater accuracy.  The choice of parameter values 
for deterministic, univariate analysis is arrived at via a literature review that reveals a 
well-estimated range of values.  In this case, the parameter value is varied because of a 
known amount of variability in the estimate. 
 A drawback of the univariate methods is the necessity of assuming that the estimate 
for each parameter is independent of the values for other parameters.  Interactions 
between parameters that lead to non-linear or multiplicative relationships with the 
outcome will be overlooked when each parameter is varied independently of the 
others.109, 111, 112 
 Multivariate sensitivity analysis involves simultaneously adjusting the values of 
two or more input parameters.  Parameters that are not independent, for instance maternal 
antibody titers and protection afforded by vaccination for measles, can be varied together.  
Of course this assumes that relationships between parameters are known.  As the number 
of parameters varied together increases, the sensitivity analysis becomes more difficult.109 
To account for such complexity, the number of values for each parameter might be 
constrained to extreme values, for instance the highest and lowest reasonable values.  
Often this is considered a best and worst case analysis; the modeler a priori assigns 
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values to parameters that are considered to cause the most favorable and unfavorable 
outcomes.  Analysis of extremes can miss important relationships between the 
parameters.  If the relationship between the input parameters and outcomes are non-
linear, then the extreme parameter values may not actually represent a best and worst 
case.  For instance, if a U-Shaped relationship exists between parameter values and the 
outcome, the a priori determined extreme values may not actually cover a best or worst 
case.  Additionally, the extreme values could represent values from the tails of an 
unknown distribution, and thus be quite unlikely to occur in combination with each 
other.109, 112 
 The most complicated type of multivariate, deterministic analysis is a full-factorial 
or n-way analysis.109, 115-117 Such an analysis investigates the outcome under every 
possible combination of parameter values.  A set of parameter values used in a single run 
of the transmission model can be thought of as a vector, and there is a vector representing 
every possible parameter combination.  The number of vectors scales a kN, where k is the 
number of parameters, and N is the number of values for that parameter.  Clearly this 
method is computationally taxing, since even a simple model can have thousands of 
vectors that need to be analyzed.  A benefit of this method is that every possible outcome 
under a certain model structure and set of assumptions is calculated.  The entire multi-
dimensional parameter space is explored.116 This method does not require assumptions 
about the distributions that values of a parameter fall into, nor does it make assumptions 
about the independence of parameter values, or that there is a monotonic relationship 
between the values of a parameter and the values of the model output.  When feasible, 
this method is highly valuable due to its thoroughness and lack of assumptions.115 
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 Probabilistic methods present more efficient means for performing multivariate 
sensitivity analysis.  In this type of sensitivity analysis, the values for each parameter 
follow some distributional form.  For instance constant mortality rates will follow an 
exponential distribution, while the infectious period of an infection could be normally 
distributed.  The distribution for each parameter is split into N intervals.  The model is 
run N times, each time with a randomly chosen input vector.  The uncertainty in each 
parameter is treated as a random variable.  A form of this type of probabilistic sensitivity 
analysis was utilized in models of HIV and tuberculosis (TB) transmission.116, 117 In these 
studies, a sampling technique known as Latin Hypercube Sampling (LHS) was used to 
randomly choose parameter vectors.  Since a sampling scheme is used, and the 
distribution that the samples are drawn from is known, the resulting output can be 
analyzed with traditional statistical methods. The benefit of this method is its efficiency.  
Rather then requiring kN input vectors, only N input vectors are needed, where N 
represents the number of values that will be drawn from the parameter distribution of 
each parameter.116   
 In a model of HIV transmission among heterosexual, intravenous drug users, 
Blower et al. used the LHS design for the first time in a deterministic, infectious disease 
transmission model.  Their model is explained by 34 ordinary differential equations with 
20 total parameters.116, 118 If five possible values were chosen for each parameter, there 
would be 3.2 x 106 input vectors under a full-factorial analysis.  Thus the efficient 
sampling design of a probabilistic sensitivity analysis was ideal.    
 One of the first steps in such a probabilistic sensitivity analysis is choosing 
probability density functions (pdfs), or distributions, describing the values of each 
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parameter.  Given that the results of this type of sensitivity analysis are analyzed 
statistically, determining these pdfs is a crucial component of the sensitivity analysis.  
Determination of these pdfs is based on direct calculation from primary data collection, 
secondary analysis of existing data, and reviews of the literature.  Sometimes, the pdf of a 
parameter will have been directly measured by calculating the mean and variance of an 
estimate.  In many cases, however, choices are based on best guesses given what data 
exist.  An illustrative example of pdf selection from the Blower et al. model is the choice 
of distribution for the progression of HIV to AIDS in pediatric patients.  At the time of 
the study, little data were available to directly measure the distributions.  However 
studies had shown that some children progressed to AIDS very quickly, measured by 
months, whereas other children took years to progress to AIDS.  Thus a bimodal 
distribution was used, specifically a Weibull distribution with two peaks.  The flexibility 
of this distribution, which ranges from a nearly exponential (early progression) to a 
nearly normal distribution (for the second peak) depending on the value of a shape 
parameter, is ideal for such a bimodal distribution.118 When estimates to support a given 
pdf are lacking, a uniform distribution is used.  If every parameter were assigned a 
uniform distribution, the analysis would be no different than a full-factorial analysis since 
each value for a parameter is chosen with equal probability. 
 Partial rank correlation coefficients (PRCC) were calculated for each parameter.  
The PRCC assesses the strength of the linear relationship between a single parameter and 
the outcome, while controlling for the values of the rest of the parameters.  The values of 
the statistic range from -1, which indicates a perfectly linear inverse relationship, and 1, 
which indicates a perfectly positive linear relationship.  A value of 0 is calculated if there 
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is no linear relationship present. This statistic requires two assumptions; (1) there is a 
monotonic relationship between the parameter and the outcome (either increasing or 
decreasing), (2) there is no interdependence or interaction between parameters.  There are 
methods to deal with covariance between parameters, but the techniques are difficult and 
the interaction must be identified in advance.119 If the assumptions are met, then the 
magnitude of the PRCC indicates how sensitive the model is to the parameter.  It is 
important to realize that this type of analysis only quantifies the uncertainty of the chosen 
transmission model structure.  Thus the results do not address generalizability to other 
settings.116   
 There are clear advantages and disadvantages to the deterministic and probabilistic 
approaches to sensitivity analysis.  The choice method relates to the motivation for the 
transmission modeling study.  If the purpose of the study is to predict general trends over 
time, then deterministic, qualitative methods should suffice.  When precise, quantitative 
estimates are required, such as in an analysis of the cost-effectiveness of a new therapy, 
then the quantitative techniques based on statistical methods are likely more apt.  It is 
also important to keep in mind the assumptions that underlie each method.  The full-
factorial, deterministic analysis makes no assumptions about the probability density 
function that describes the values of a parameter or about the interrelationship between 
parameters in the model.  It also makes no assumption regarding the linearity of the 
relationship between a parameter and the chosen outcome.  When assumptions of 
independence and monotonicity are met, the probabilistic methods provide the most 
information in the most efficient fashion. 
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III. Statement of Specific Aims 
A. Aim 1 
Aim: Measure the short and long-term incidence of natural and breakthrough 
varicella after introduction of a 2-dose vaccination program, paying special interest to the 
epidemiology in the next 20 years. 
Rationale: The short and long-term effect of a 2-dose vaccination schedule is 
unknown. Of immediate concern is the magnitude of a post-vaccination resurgent 
epidemic that could occur in the next 10 to 20 years. 
Hypothesis: A resurgent epidemic is unavoidable, even with the introduction of a 
two-dose vaccine program.  A two-dose vaccine program will decrease both natural and 
breakthrough varicella rates relative to a single dose program. 
B. Aim 2 
Aim2: Demonstrate methods for a systematic sensitivity analysis for transmission 
models that can be applied to other settings, standardizing the methodology and 
increasing the generalizability of different models. 
Rationale: Sensitivity analyses are often ignored or given superficial treatment in 
transmission models, limiting the assessment of model uncertainty and decreasing 
comparability between different models.  
Hypothesis: A systematic method of sensitivity analysis will demonstrate a high 
degree of uncertainty in the current model, and will prove to be sufficiently general that it 
can be applied in a wide variety of model settings. 
IV. Methods 
  
 A. Study Design 
 
 An age-structured, deterministic, compartmental model will be specified.  The 
model consists of fourteen ordinary differential equations.  The model structure and age-
specific mixing patterns are adapted from a previously described model1, with updates to 
the structure and parameters reflecting the observed epidemiology of the last 13 years.   
The sensitivity analysis makes use of qualitative, deterministic techniques that measures 
the sensitivity of the model to every possible combination of input parameter values.  
Univariate and multivariate techniques are outlined.  These methods provide a systematic 
method for performing a qualitative sensitivity analysis, which should be generalizable to 
other modeling studies in different settings.   
 
 B. The Varicella Transmission Model 
The population is split into 66 age cohorts for 0 to 64 years, anyone 65 years and 
older are in the 66th cohort.  Births are added as partial susceptibles the 0 year age class, 
and all mortality will occur in the 65 years and older group.  Birth and death rates, µ, are 
equal to maintain a constant population size.  Births, aging, and mortality happen at the 
end of each year, thus maintaining discrete age cohorts. The mixing patterns and contact 
rates are described by what Brisson et al. described as the base-case and matrix 1 who 
acquires infection from whom (WAIFW) (figure 4.2).1 Discrete time steps of 0.1 days are 
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used, and the model runs from one year before the implementation of routine vaccination 
in 1995 until 2095. 
 The population is divided into mutually exclusive, epidemiologically relevant 
compartments (figure 4.1).  Children are born into the susceptible class (S) at age 0.  To 
account for maternal antibody protection, children in this age class are ½ as infectious as 
a susceptible in any other age class.  Effective contact with an infectious individual 
moves susceptibles into latent class (E) at the rate determined by the force of infection, 
λ(a,t), where individuals are infected but not yet infectious, becoming infectious (I) at 
rate σ (where 1/σ equals the duration of the latent period), before finally recovering with 
permanent immunity (R) at rate γ (1/γ equals the duration of the infectious period). 
Susceptibles are vaccinated at rate c1, which is set to 90%, rounded up from the US 
average coverage rate of 88%.2  Vaccination of susceptibles moves them into the 
vaccinated protected class (VP) with probability (1-ϕ), which is the probability that a full 
immune response is mounted, or to a vaccinated susceptible class (VS) with probability 
ϕ, which is the probability of mounting a sub-optimal immune response.  Members of VP 
are completely but temporarily protected against infection, while the VS class consists of 
individuals who are susceptible to infection, though less so than members of S.  Infection 
of VS is deemed “breakthrough infection.”  
Members of the VP class become permanently immune if they have effective 
contact with an infectious individual at rate kλ(a,t), or if they receive a second dose of 
vaccine at coverage rate c2.  Either event moves them into a permanently immune class, 
VV.  Exposure of the VS class to infectious individuals leads to breakthrough infection at 
rate bλ(a,t), where b represents the relative susceptibility of VS compared with S, or they 
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become permanently immune and move into the VV class at rate (1-b)λ(a,t).  Members of 
VS also become permanently immune after a second dose of vaccine at rate c2. 
Breakthrough infections are either mild (VEm and VIm) or severe (VEs and VIs). 
Movement to VEm vs. VEs is determined by the proportion of effective contacts that are 
breakthrough cases (πa,t).  Mild cases are assumed to be 30% as infectious (m) as a severe 
breakthrough or natural case based on a household contact study.3 From this same study, 
we assume that 90% (α) of VS move to VEm if exposed to a breakthrough case, whereas 
75% (ε) of VS move to VEm if exposure is to a naturally infectious individual (I), or to a 
severe, fully infectious breakthrough case (VEs).3 Immunity following breakthrough 
infection is, similar to natural disease, considered to be lifelong; additionally 
breakthrough cases have the same latent and infectious periods as natural cases.4   
Rather than modeling the impact of herpes zoster directly, a constant is added to 
the force of infection to account for zoster related transmission.1 The parameters that 
define the transitions between compartments are assigned values based on relevant data 
from the literature review, and are presented in table 4.1.  
The model runs by integrating a set of 14 ordinary differential equations (figure 
4.2). A single dose vaccine program will be run for 10 years in the model, with the first 
dose of vaccine given to children as they turn 1 year of age; after 10 years second doses 
will be given to 2 or 5 year olds at various coverage rates.  A comparison model is run 
that does not have a second dose.  The simulations are run using newly written C++ code 
(developed by SV and AL).  The incidence rates from 2005 to 2025 under one-dose and 
two-dose regimes where the second dose is given to either 2 or 5 year olds are calculated.  
This includes overall incidence rates, incidence rates in the unvaccinated, and 
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breakthrough incidence rates.  Additionally, age-specific incidence rates are examined to 
determine the change in the average age of infection in a one vs. two-dose scheme. 
Incidence rates after 100 years are examined in the same way, to determine the long-term 
expected outcomes. 
 
C. Sensitivity Analysis 
 1. Validation of baseline parameter values. 
 To validate the choices for a base set of parameter values, the results of models 
with presumed baseline values are compared against data of the observed annual varicella 
incidence rates since 1995, when vaccination started. 
 
 2. Definition of outcomes 
 The sensitivity of two different outcomes from the model is assessed against 
changes in the input parameter values.  The first outcome is the post-vaccination 
epidemic peak incidence rate.  This is the instantaneous, per-capita incidence of infection 
in the population.  A second distinct but related outcome is the cumulative number of 
infections from 2005 to 2025, which covers the time period of the post-vaccination 
epidemic.  These outcomes are chosen based on their epidemiologic relevance.  The 
incidence rate provides an idea of the short term needs of public health planners, whereas 
the cumulative incidence determines the overall public health burden of the outbreak. 
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 3. Design of the sensitivity analysis 
 A full factorial analysis is used.  In such an analysis, the transmission model gets 
run using every possible combination of parameter values.  Each combination can be 
thought of as an input vector, with a single value for each parameter.5-8 To create vectors, 
the continuous distribution of parameters was reduced to a series of discrete values close 
enough together as to not miss any possible departures from linearity in the relationship 
between the parameter and output.  For parameters distributed between 0 and 1, we added 
or subtracted 0.05 from the base value to the upper and lower values of the range.  The 
range of values is given in table 4.2. 
 Keeping with the qualitative nature of this sensitivity analysis, which is 
appropriate given the qualitative nature of the transmission model, univariate 
relationships are analyzed and displayed in spider plots.  The relative change in the 
output from the baseline output is plotted against the relative change in parameter values 
from their baseline value.  With this method it is possible to examine the relationship 
between changes in a single parameter value with changes in the output. 
We use box plots to examine every possible output value across different values 
of a single parameter.  The box plots are useful in determining the occurrence of 
parameter interactions, departure from linearity, and for examining the variability in the 
outcome associated with specific values of a parameter.  This technique is not typically 
performed, but it provides much more information than spider plots or other univariate 
graphs. 
Next, an analysis of two different scenarios is presented.  Typically modelers will 
a priori determine “best” and “worst” case input vectors.  In our case, the worst-case 
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vector assigns the following values: ϕ=0.4, b=0.9, m=0.8, and 1/ω=1 year.  The best-case 
scenario uses the opposite extremes where: ϕ=0.05, b=0.3, m=0.2, and ω=0.  Examining 
only these extremes implicitly assumes a monotonic relationship between the best and 
worst case.7, 9  
A benefit of the full factorial analysis is that every possible outcome can be 
examined.10, 11 Then outcomes that truly are the best or worst, where very low or high 
numbers are infected, can be examined and the vector that gave rise to such an outcome 
determined.  These vectors may differ from what was a priori determined as a best or 
worst case vector, and such evidence of a non-monotonic relationship provides clues 
about the presence of interactions between parameters. 
Finally we assess linearity of the each parameter with the number of cases using 
the partial correlation coefficient.  This statistic gives a value of -1 to 1, which represents 
complete inverse and positive linearity, with 0 indicating the lack of a linear relationship.  
The coefficients for each parameter are controlled for every other parameter.  It is 
essentially a quantification of the results of the spider and box plots.  This is a useful 
technique, but it assumes independent relationships amongst the parameters.  If there is 
no evidence of a linear relationship, this does not mean there is not another relationship.12 
The model is run with every possible parameter combination.  The outcomes of this full-
factorial analysis are compared, and the parameters leading to the largest changes in 
outcome measures are identified.  Additionally, interactions are assessed in multivariate 
analysis where parameter-outcome relationships are examined under different values for 
a second-parameter.  The extreme values for the outcome (highest and lowest peak 
incidence rate and total incidence) are singled out, and the parameter vectors that give 
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rise to these extreme values is determined.  The results of this analysis are presented 
graphically, providing a qualitative determination of sensitivity and uncertainty in the 
model outcomes and parameters.  The results of the simulations are analyzed with 
STATA version 9 (College Station, Texas).  The simulations were created with 
handwritten C++ software. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 68 
Figure 4.1. The Base Model, compartments and flows.  See table 4.1 for explanations of 
parameters that are numbered here. 
S E I R
VEm VIm VRm
VEs VIs VRs
VP
VV
VS
1. Births
2. Infection
5. Full 
response
6. Sub-optimal 
response
7. Waning 
immunity
3. Becoming
infectious
3. Becoming
infectious
4. Recovery
Vaccination
9. 
Exogenous 
boosting
8. Second 
dose
10. Second 
dose
11. 
Exogenous 
boosting
12. Breakthrough 
infection (mild)
13. Breakthrough 
infection (severe)
4. Recovery
4. Recovery3. Becominginfectious
S=Susceptible to infection; E = Infected but not yet infectious; I=Infectious; 
R=Recovered and permanently immune; VP = Vaccinated protected (full but temporary 
protection from infection after a single dose of vaccine); VS = Vaccinated susceptibles 
(sub-optimal response and thus somewhat susceptible to infection after a single dose); 
VE= vaccinated, infected but not yet infectious, VI = vaccinated infectious, e.g. a 
breakthrough case; VR=Recovered and permanently immune after breakthrough 
infection; the subscripts m and s refer to mild disease and severe disease respectively; 
VV=Permanently immune from either two doses of vaccine, or one dose of vaccine 
followed exogenous boosting of immunity without becoming infectious. 
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Table 4.1.  Description and values of parameters and flows between compartments. 
 
 Flow                  Parameter Value Description 
1 Births 
Deaths 
B 
µa 
400,000 
0 for a<65, 0.1/year for 
a≥65 
Births per year, balances deaths 
 
Death Rate 
2 S  E λa,t 
 
 
λz 
Varies with time and 
age. 
0.00000274  
Age and time dependent force of 
infection 
 
Force of infection from zoster 
  z a 0.5 for a=0, 0 for a≥1 Reduced susceptibility from maternal 
antibodies in infants 
  m 0.33 Relative infectiousness of mild 
breakthrough cases 
3 E I σ 0.0714/day 1/14 day latent period 
4 I R 
VImVRm 
VIsVIs 
γ 0.1429/day 1/7 day infectious period 
5 S VP c1 0 or 0.90 First dose coverage rate 
  c2 0.5 or 0.75 Second dose coverage rate 
  (1-ϕ) 0.75 Successful vaccination probability 
6 S VS ϕ 0.25 Sub-optimal response probability 
7 VP VS ω 0.0333/year Rate of waning of vaccine induced 
immunity 
8 VP VV c2 0.5 or 0.75 See 5 
9 VP VV k 0.91 Exogenous boosting probability 
10 VSVV c2 0.5 or 0.75 See 5 
11 VS VV (1-b) 0.25 Exogenous boosting probability 
12 VS VEm α 0.9 Probability of mild disease if exposure 
was to VIm 
  ε 0.75 Probability of mild disease if exposure 
was to VIs or I 
  πa,t Varies Proportion of infectious contacts with 
breakthrough disease 
13 VS VEs (1-α) 0.1 Probability of severe disease if 
exposure was to VIm 
  (1-ε) 0.25 Probability of severe disease if 
exposure was to VIs, or I 
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Table 2. Mathematical Representation of the Model (Numbers below terms link 
these equations with the pathways in figure 1.) Births, deaths, aging, and vaccination 
events are treated as discrete processes that occur at year-end. These terms, therefore, do 
not appear in the differential equations.                       
€ 
dSa,t
dt = −zaλa,tSa,t
         2
dEa,t
dt = zaλa,tSa,t −σEa,t
       2              3
dIa,t
dt =σ Ea,t − γIa,t
     3          4
dRa,t
dt = γ Ia,t
   4
dVPa,t
dt = − ω + kλa,t( )VPa,t
      7       9
dVSa,t
dt =ωVPa,t − λa,tVSa,t
       7     11,12,13
dVVa,t
dt = kλa,tVPa,t + 1− b( )λa,tVSa,t
       9                  11
dVEma,t
dt = απ a,t + ε 1−π a,t{ }( )bλa,tVSa,t −σVEma,t
     12            12                                3
dVIma,t
dt =σVEma,t − γ + µa( )VIma,t
      3              4      
dVRma,t
dt = γVIma,t
   4
dVEsa,t
dt = 1−α{ }π a,t + 1−ε{ } 1−π a,t{ }( )bλa,tVSa,t −σVEsa,t
        13                       13                                    3
dVIsa,t
dt =σVEsa,t − γVIsa,t
    3               4
dVRsa,t
dt = γVIsa,t
    4
 
 
 
€ 
λa,t = βa, ′ a 
I ′ a ,t
N ′ a ,t
+
VIs ′ a ,t
N ′ a ,t
+ m VIm ′ a ,tN ′ a ,t
 
 
 
 
 
 ′ a = 0
65
∑ + λZ
π a,t =
βa, ′ a 
VIs ′ a ,t
N ′ a ,t
+ m VIm ′ a ,tN ′ a ,t
 
 
 
 
 
 ′ a = 0
65
∑
λa,t
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Figure 4.2a Brisson et al. Base matrix.  β values are contact and transmission rates 
per 100 days.  The first row and column are the age groups. 
 
Figure 4.2b. Brisson et al. Matrix 1  
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Table 4.3. Base parameter values and range used in sensitivity analysis. 
Parameter Base Value Range Description 
ϕ 0.25 0.05 – 0.4  Sub-Optimal Response 
Rate 
b 0.6 0.3 – 0.9  Residual susceptibility 
of vaccinated 
susceptibles 
m 0.33 
 
0.2 – 0.8  Reduced infectiousness 
of mild breakthrough 
cases 
c2 
 
0.5 or 0.75 
 
0.5 or 0.75  Second dose coverage 
rate 
ω 0.0333/year 
(30 Year 
Duration) 
1 to 100 year duration  Waning of vaccine 
induced immunity 
 
Mixing 
Matrix 
 
Base and 
Matrix 1 
 N/A   Refer to figure 4.2  
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A. Abstract 
In 1995 in the United States implemented a single-dose strategy of varicella 
vaccination in infants.  Varicella incidence, morbidity, and mortality declined 
dramatically, though outbreaks continued, even in highly vaccinated populations, and the 
incidence of varicella began rising in 2003.  These events prompted the recommendation 
of a two-dose vaccination strategy in 2005.  A deterministic, age-structured transmission 
model of the two-dose strategy predicts a large epidemic of varicella in the near future, 
even with high second-dose coverage rates.  In the long-term, incidence rates under a 
two-dose regime will be 10% or less compared with pre-vaccination rates, compared with 
up to 50% with a continued one-dose strategy.  Varicella cases will consist mostly of 
mild, breakthrough disease in previously vaccinated individuals.  As the average age of 
infection increases, a higher proportion of varicella infections will occur in the 15 to 25 
year old age group, raising concern over congenital varicella syndrome. 
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B. Introduction 
Between 1995 and 2003 the incidence, morbidity, and mortality from varicella in 
the United States dropped by roughly 80% as a result of the introduction of the Varicella 
Zoster Virus (VZV) vaccine in 1995.1 The epidemiology of varicella in the United States 
in now largely characterized by outbreaks in daycare facilities and elementary schools, 
where observed attack rates have been high in both vaccinated and unvaccinated children.  
In some cases, vaccine effectiveness has fallen below 50%, compared to the 80% to 90% 
vaccine efficacy estimates obtained in pre-licensure vaccine trials.2-4   
The rate of breakthrough disease, defined as varicella in a vaccinated individual, 
is roughly 2%-3% per year, with larger attack rates during outbreaks.2,3,5-12 Breakthrough 
disease is typically mild; about 75% of cases have fewer than 50 vesicles and are 30% to 
50% as infectious as more severe breakthrough or natural cases.  Breakthrough cases with 
more than 50 lesions are nearly as infectious as naturally infected cases, and are similarly 
ill.13 The fact that breakthrough infections are typically mild is evidence of some degree 
of protection among these vaccinees, enough to attenuate the disease but not enough to 
prevent infection.  Several serological studies have shown that breakthrough cases were 
often seronegative after vaccination. This suggests an important role for cellular 
immunity to provide protection against full-blown disease.14,15 
Younger ages of vaccination (<15 months) and time since vaccination (5+ years) 
have been associated with breakthrough disease in several outbreaks.  Primary vaccine 
failure, maternal antibodies, sub-optimal immune response, and waning of vaccine-
induced immunity have thus been posited as potential mechanisms for breakthrough 
disease.2,3,8,16-19  Primary vaccine failure is treated as different phenomena by different 
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authors, with some referring to the situations of improper injection, expired vaccine, and 
instances where the vaccinee mounts no immune response at all, while others refer to 
situations of sub-optimal immune response.13,20  A recent population-based study utilized 
the highly sensitive and specific fluorescent antibody against membrane antigen test, and 
found that only 76% of vaccinees seroconverted after one-dose, indicating that primary 
failure or suboptimal vaccine response due to a weak humoral response may be more 
frequent than previously believed based on studies using the gpELISA assay.20  We 
ignore primary failure as described above, and concentrate on the sub-optimal immune 
response.   
Interference of maternal antibodies with vaccination has been demonstrated for 
other vaccine preventable childhood diseases such as measles21, but is unlikely to occur 
for varicella vaccine as maternal antibodies against VZV are typically not longer present 
at 12-months of age.22   
Waning of vaccine-induced immunity has been difficult to study.  More than 90% 
of single-dose vaccinees had demonstrable antibodies in pre-licensure clinical trials, with 
a persistent titer for 6-10 years, but these trials took place when the background rate of 
varicella was still very high, resulting in exposure to wild-type virus.5,23-25 
The Advisory Committee on Immunization Practices (ACIP) recommended the 
institution of a 2-dose vaccine regimen in 2005, following a string of well-publicized 
varicella outbreaks in situations with high vaccine coverage.1 The first dose continues to 
be given at 12-15 months, and the second dose is recommended for 4 to 6 year olds, as 
pre-school begins.1 Some have argued for earlier administration of the second dose.26 
 77 
While a number of modeling studies investigated the effects of a single dose regimen, no 
predictions have been made regarding the effect of a second dose.7,27,28 
In this study, we explore the impact of the implementation of a two-dose 
campaign on varicella epidemiology over time, the effect on the peak age of infection, 
and the relative number of mild vs. severe breakthrough cases.  In addition, we assess the 
optimal timing of the second dose in light of calls for scrutiny of the current 
recommendation.26 
 
C. Methods 
A deterministic, age-structured model was used to examine the transmission 
dynamics of varicella zoster virus (VZV).  The model is adapted from Brisson et al., with 
differences taking into account recent findings and refining the model structure and 
parameterization.2,28 The structure of the model is given in Figure 5.1; model parameters 
are presented in Table 5.1. 
Birth and aging occur at the beginning of each year, with the entire age cohort 
aging at once.  Individuals are born into the susceptible class.   There are 66 yearly age 
classes, with those 65 years and older grouped together in the oldest age group, N65. 
Mortality rates (µ) are age-dependent, where µa equals zero if a is less than 65, and 
equals 0.1 otherwise, resulting in an average lifespan of 75 years.  Before age 1, 
individuals are half as susceptible to infection as other age groups, accounting for 
maternal antibody protection (z); there is no maternal antibody interference with 
vaccination.22  Effective contacts, i.e. ones that lead to infection, occur at rate λa,t, which 
is the force of infection, and newly infected susceptibles move into an infected but not 
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infectious compartment (E).  Individuals pass from this exposed class to the infectious 
class (I), at rate σ (1/σ is equal to the latent period of 14 days).  Cases recover to a 
permanently immune class (R) at a constant rate γ (1/γ is equal to the infectious period of 
7 days).  This infection pathway is referred to as natural infection, i.e. infection in a 
previously unvaccinated individual.  Immunity from natural infection is assumed to be 
life-long. 
Vaccination of susceptibles occurs as they turn 1 year of age.  Vaccination rates 
are taken from the current U.S. average of 88%, rounded to 90%.30 The parameter c1 
holds this value.  Vaccinees move into either a temporarily but completely protected class 
(VP), or to a partially susceptible class (VS) with probability ϕ.  This represents the 
probability that an individual will have a sub-optimal response to vaccination, and is set 
equal to 25% in the base case, an estimate based on a recent seroprevalence study and 
household contact study.13,20 
From VP, individuals can flow into the VS compartment at waning rate ω.  
Estimates of the duration of vaccine induced immunity, based on seropositivity, range 
from 2 years to lifelong.3,11,18,31 Alternatively, individuals in VP can enter the 
permanently immune class VV after receiving a second-dose of vaccine, at coverage rate 
c2, or upon exposure to an infectious individual at rate k λa,t.  The second dose is given at 
5 years of age to reflect the current recommendations, and at 2 years of age to inspect an 
alternate strategy.  The parameter k modifies the rate at which individuals in VP move to 
VV after an effective contact.  Thus (1-k) of VP who have an effective contact remain in 
VP after such contact. 
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We assume permanent immunity for the VV class based on two-dose efficacy 
trials.32,33  Rates for a second dose are assumed to be less than coverage rates for the first 
dose; similar to what is observed in other multi-dose regimens.30 
Members of VS who have effective contact with an infectious individual become 
infected (breakthrough infection) at rate b λ(a,t), or become permanently immune by 
moving into VV at rate (1-b)λ(a,t).  The partial susceptibility, b, of vaccinees relative to 
unvaccinated susceptibles is set at 60% based on estimates from household contact attack 
rates and values used in other modeling studies.7,20,28,32-34  
 Breakthrough infections are either mild (VEm and VIm) or severe (VEs and VIs). 
The proportion of effective contacts that are with breakthrough cases (πa,t) determines the 
proportion of VS who move to VEm vs. VEs.  Mild cases are assumed to be 33% as 
infectious (m) as a severe breakthrough or natural case.13,35 Based on a household contact 
study, we assume that 90% (α) of VS move to VEm if effectively exposed to a 
breakthrough case, whereas 75% (ε) of VS move to VEm if effective exposure is to a 
naturally infectious individual (I), or to a severe, fully infectious breakthrough case 
(VEs).13  Immunity following breakthrough infection is, similar to natural disease, 
considered to be life-long; additionally breakthrough cases have the same latent and 
infectious periods as natural cases.35   
The who acquires infection from whom (WAIFW) matrix, defines the effective 
contact rate, β a,a', between age groups a and a’, and consists of eight age classes: infants 
(0-1), pre-schoolers (2-4), younger school children (5-11), adolescents (12-18), young 
adults (19-24), parental ages (25-44), older adults (45-64), and seniors (65+).36,37 The 
effective contact rate accounts for the actual contact rate, and the transmission probability 
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given a contact between a (naive) susceptible and (natural) infective.  The matrices used 
are identical to the base matrix and matrix 1 of Brisson et al.28 The base matrix has high 
contact rates among school children, between parents and infants, and within 15 to 18 
year olds, in addition to very high contact rates within the 19-24 year age group.  Matrix 
1 is similar, but contact within the 19-24 year age class is decreased by 33%.  Rather than 
modeling the impact of herpes zoster directly, a constant is added to the force of infection 
to account for zoster related transmission.28  
The model runs by integrating a set of differential equations (table 5.2) with a 
one-day time-step.  The model starts in 1994 at the pre-vaccine endemic equilibrium and 
runs for 100 years post vaccine implementation in 1995.  The second dose campaign 
(when present) is implemented in 2005, corresponding to the US recommendations. 
A sensitivity analysis was performed to assess the effect of changing parameter 
values on the output of the model. Univariate and multivariate, deterministic sensitivity 
analyses were performed.  First we changed the value of a parameter of interest against a 
background of the base values for other parameters.  Second we held the parameter of 
interest at a constant value, compared to a background of all possible model outcomes 
from variation in all other parameters.  The outcomes measured for the sensitivity 
analysis were the peak post-honeymoon incidence, and the total number of cases during 
this epidemic. 
 The model simulations were run from handwritten C++ code (SV and AL), 
statistics and graphics were produced with STATA v9.0 (College Station, Texas). 
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D. Results 
The predicted pre-vaccination era incidence rate of 13.4 cases per 1,000 
population is similar to pre-vaccination data observed in the United States and estimates 
from other modeling studies, which gives us confidence in our model.28,38  The age-
specific incidence rates per 1,000 person years are 86.5, 73.29, 21.43, and 8.72 for the 0-
4, 5-9, 10-14, and 15-18 year age classes respectively, and are also similar to the 
observed rates in the U.S. before vaccination.  For instance, data from the Behavioral 
Risk Factor Surveillance Study (BRFSS) observed incidence rates of 100.0, 78.9, and 
13.8 for the 0-4, 5-9, and 10-14 year age classes respectively.39 
The model output for the first 10 years of routine single dose varicella vaccination 
program predicts a dramatic decrease in incidence, followed by a temporary increase a 
few years later and a resurgence beginning in 2003.  The predicted pattern is similar to 
what has been observed in the United States, though the model has the temporary 
increase in incidence occurring in 1999 rather than 1997 as was observed (figure 5.2).  
The resurgence that begins in 2003 is predicted to continue, and reach high incidence 
rates of up to 50% to 80% of the pre-vaccine incidence (figure 5.3).  This so-called “post-
honeymoon” epidemic is a phenomenon that has been seen following other wide-scale 
vaccination campaigns, and has been predicted by other varicella models.28,40-42 
Following a brief lull, a second epidemic occurs around 2025, 10 years after the first, 
followed by an approach to the steady state incidence rate 50 years after the introduction 
of the vaccine program.   
The two dose vaccination model predicts that the currently observed resurgence 
will continue (figure 5.3). However, with the two-dose strategy the second epidemic is 
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prevented, and much lower incidence rates are achieved at steady state.  Within 50 years 
after the introduction of the two-dose strategy, the incidence drops to very low rates and 
remains at incidence levels 10% or less than those observed in the pre-vaccine era.  
Furthermore, when 75% coverage of the second dose is achieved, the disease is nearly 
eliminated.  Changing the age of administration of a second dose to 2 years of age 
produces a much higher resurgent peak (figure 5.3).  In the long-term, the age of 
administration makes no difference.  
Before 2005, the predicted incidences are largely independent of the WAIFW 
matrix used. However, following the beginning of the two-dose strategy in 2005, the 
predicted outcomes diverge depending on whether the base mixing matrix or mixing 
matrix 1 is used.  The conclusion that we are at the cusp of a varicella epidemic remains 
unchanged; however the magnitude of the epidemic we can expect to occur depends on 
which of the two matrices best represents the true contact patterns in the United States 
(data not shown). 
The proportion of each age group in classes R, VRm, or VRs, makes up the 
model-predicted age-specific seroprevalence from prior infection.  We do not include 
vaccinated individuals who were never infected individuals in these seroprevalence 
curves. The pre-vaccination seroprevalence in the model mirrors the seroprevalence 
curves for most temperate, industrialized countries (figure 5.4).43-45  Similar to 
observational data, the model predicts that the average age of infection will increase as 
time since vaccination increases (figure 5.4).  Following 10 years of single dose 
vaccination, the peak incidence occurs between about 10 years of age and 15 years 
(evidenced by the steepest part of the slope in the prevalence curves).46 The model 
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predicts that by 2015, a large proportion of varicella infections will occur in the 16 to 24 
year age group. Implementing a second dose of vaccine does not substantially influence 
the changes in the average age of infection. 
The relative amounts of mild and severe breakthrough disease, and disease in the 
unvaccinated, is shown in figure 5.5.  Over time, mild breakthrough disease becomes the 
prominent form of chickenpox.  In the short term, higher vaccination coverage favors 
mild disease, but as the incidence approaches the post-vaccination steady state, the 
relative amounts of the disease types is identical regardless of the second dose coverage 
rate.  The age of second dose vaccination did not impact the percentages of disease types 
(not shown).  
The sensitivity analysis revealed that breakthrough incidence was more sensitive 
to model inputs than the incidence in unvaccinated individuals.  The model was most 
sensitive to the estimated rate of waning of vaccine-induced immunity, and the influence 
of other parameters was dependent upon the value of this parameter.  This emphasizes the 
need for more accurate estimates of the rate of waning of vaccine-induced immunity.   
 
E. Discussion 
 This study predicts that the resurgence in varicella incidence that has been 
observed since 2003 will continue and peak in 2015, 20 years after the beginning of the 
single dose varicella vaccination strategy.  The resurgence is a result of a buildup of 
susceptibles (S) protected by herd-immunity, as well as a buildup of partially susceptible 
vaccinated individuals (VS) due to waning immunity or sub-optimal response to vaccine, 
compounded by the decreasing circulation of VZV.  The magnitude of the resurgent peak 
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is striking, with incidence rates approaching pre-vaccination rates.  While this seems 
unrealistic at first glance, such peaks have been observed in post-vaccination measles 
epidemics as well as by other models of varicella transmission.28,40  The incidence rates at 
the eventual steady state under a one-dose strategy are 50% to 60% of the prevaccination 
incidence rates. 
 A two dose campaign will result in markedly lower incidence in the long term, 
even at modest (50%) second dose coverage rates, but will only minimally attenuate the 
size of the short-term resurgence.  Concern over the timing of the second dose has been 
expressed due to the possibility of breakthrough infection occurring in pre-schoolers who 
had a suboptimal response to the first dose of vaccine.26 Our results predict a similar 
steady state incidence between administration of the second dose at 2 or 5 years of age, 
but a second dose at age 2 years results in a higher peak incidence in the next 15 years.   
 Over time, mild breakthrough varicella will predominate.  Second dose coverage 
rates and age at vaccination does not appreciably alter the relative proportions of disease 
caused by natural, severe breakthrough, or mild breakthrough illness.  The age 
distribution of varicella incidence will also change over time.  Currently, the highest 
incidence rates are seen between 10 and 14 years of age.  As the average age of infection 
increases, a higher proportion of varicella infections will occur in the 15 to 25 year old 
age group, raising concern over the incidence of congenital varicella. Such perverse 
effects of vaccination are well known for rubella.47 However, as the majority of these 
cases will have mild breakthrough disease they may not suffer the severe adverse effects 
of natural infection seen in older age groups.  It is also unknown how the fetus is affected 
by breakthrough varicella relative to natural disease. 
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There are several limitations to this study.  As with any modeling study, 
uncertainty remains about parameter values, model structure and assumptions.  The 
output of this model is highly sensitive to the duration of immunity, which has the least 
certain estimates of any parameters in our model. Another problem is the precision of the 
estimates for contact rates, especially in the older age groups. Mixing matrices are 
determined by the pre-vaccination age specific changes in incidence.  Since most older 
children and adults have experienced past infection, there is very little change in the 
seroprevalence with age, and determination of their contact rates become problematic.  
Mixing matrices that are based on observed contact rates, collected by using diaries, 
rather than rates inferred from the age specific forces of infection, will greatly improve 
the accuracy of future models.33,36,42,48 
Despite these uncertainties, the general qualitative predictions of this model are 
likely to hold true.  In contrast with previous modeling studies, this study has the benefit 
of 10 years of varicella incidence data collected since the start of vaccination to validate 
its results.  The predictions of the model for the years 1995 to 2006 are highly consistent 
with what has been observed in terms of incidence rates, seroprevalence, and an 
increasing burden in older age groups.  We therefore are confident that the resurgence of 
varicella will continue for the next 10 to 15 years, despite a successfully implemented 
two-dose campaign.  
The varicella vaccine is already refused more than any other mandatory childhood 
vaccine in the United States.49,50 Outbreaks are well publicized, and occur in highly 
vaccinated populations.  This fuels a belief that the vaccine is not beneficial. 
Unfortunately, it appears that this belief may persist over the next 10 years.  Our model, 
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to our knowledge the first to examine the effect of two doses of vaccine, indicates that the 
two-dose campaign will be successful in greatly decreasing the incidence of varicella 
over time.  Thus the short-term increase in incidence, which appears to be unavoidable, 
should not be taken as evidence that the vaccine is ineffective, or that the current 
recommendations from ACIP are incorrect.  Whether a concerned public or policy 
makers will be patient enough to wait for the benefits of the current recommendations to 
appear is not known, however the results of our study suggest that patience will 
eventually pay off. 
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Figure 5.1. Model Structure 
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Figure 5.1.  The Base Model, Illustration of the flows between different compartments.  
The processes are numbered and defined in Table 1. For clarity, arrows depicting deaths 
are omitted. S=Susceptible to infection; E = Infected but not yet infectious; I=Infectious; 
R=Recovered and permanently immune; VP = Vaccinated protected (full but temporary 
protection from infection after a single dose of vaccine); VS = Vaccinated susceptibles 
(sub-optimal response and thus somewhat susceptible to infection after a single dose); 
VE= vaccinated, infected but not yet infectious, VI = vaccinated infectious, e.g. a 
breakthrough case; VR=Recovered and permanently immune after breakthrough 
infection; the subscripts m and s refer to mild disease and severe disease respectively; 
VV=Permanently immune from either two doses of vaccine, or one dose of vaccine 
followed exogenous boosting of immunity without becoming infectious. 
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Table 5.1.  Description and values of parameters and flows between compartments. 
 
 Flow                  Parameter Value Description 
1 Births 
Deaths 
B 
µa 
400,000/year 
0 for a<65, 0.1/year for 
a≥65 
Annual birth rate, balances deaths 
Death Rate 
2 S  E λa,t 
 
λz 
Varies with time and 
age. 
0.00000274 
Age and time dependent force of 
infection Additional force of infection from zoster  
  z a 0.5 for a=0, 0 for a≥1 Reduced susceptibility from maternal 
antibodies in infants 
  m 0.33 Relative infectiousness of mild 
breakthrough cases 
3 E I σ 0.0714/day 1/14 day latent period 
4 I R 
VImVRm 
VIsVIs 
γ 0.1429/day 1/7 day infectious period 
5 S VP c1 0 or 0.90 First dose coverage rate 
  c2 0.5 or 0.75 Second dose coverage rate 
  (1-ϕ) 0.75 Successful vaccination probability 
6 S VS ϕ 0.25 Sub-optimal response probability 
7 VP VS ω 0.0333/year Rate of waning of vaccine induced 
immunity 
8 VP VV c2 0.5 or 0.75 See 5 
9 VP VV k 0.91 Exogenous boosting probability 
10 VSVV c2 0.5 or 0.75 See 5 
11 VS VV (1-b) 0.25 Exogenous boosting probability 
12 VS VEm α 0.9 Probability of mild disease if effective 
contact was with VIm 
  ε 0.75 Probability of mild disease if effective 
contact was with VIs or I 
  πa,t Varies Proportion of infectious contacts with 
breakthrough disease 
13 VS VEs (1-α) 0.1 Probability of severe disease if 
effective contact was with VIm 
  (1-ε) 0.25 Probability of severe disease if 
effective contact was with VIs, or I 
 
 89 
Table 2. Mathematical Representation of the Model (Numbers below terms link 
these equations with the pathways in figure 1.) Births, deaths, aging, and vaccination 
events are treated as discrete processes that occur at year-end. These terms, therefore, do 
not appear in the differential equations.                       
€ 
dSa,t
dt = −zaλa,tSa,t
         2
dEa,t
dt = zaλa,tSa,t −σEa,t
       2              3
dIa,t
dt =σ Ea,t − γIa,t
     3          4
dRa,t
dt = γ Ia,t
   4
dVPa,t
dt = − ω + kλa,t( )VPa,t
      7       9
dVSa,t
dt =ωVPa,t − λa,tVSa,t
       7     11,12,13
dVVa,t
dt = kλa,tVPa,t + 1− b( )λa,tVSa,t
       9                  11
dVEma,t
dt = απ a,t + ε 1−π a,t{ }( )bλa,tVSa,t −σVEma,t
     12            12                                3
dVIma,t
dt =σVEma,t − γVIma,t
      3              4      
dVRma,t
dt = γVIma,t
   4
dVEsa,t
dt = 1−α{ }π a,t + 1−ε{ } 1−π a,t{ }( )bλa,tVSa,t −σVEsa,t
        13                       13                                    3
dVIsa,t
dt =σVEsa,t − γVIsa,t
    3               4
dVRsa,t
dt = γVIsa,t
    4
 
 
 
€ 
λa,t = βa, ′ a 
I ′ a ,t
N ′ a ,t
+
VIs ′ a ,t
N ′ a ,t
+ m VIm ′ a ,tN ′ a ,t
 
 
 
 
 
 ′ a = 0
65
∑ + λZ
π a,t =
βa, ′ a 
VIs ′ a ,t
N ′ a ,t
+ m VIm ′ a ,tN ′ a ,t
 
 
 
 
 
 ′ a = 0
65
∑
λa,t
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Figure 5.2. Base model validation: Model Predicted Incidence (Dashed) and Observed 
Incidence (Solid) from 1994 to 2006.  Both curves are scaled relative to their 1994 rates 
to facilitate comparisons. 
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Figure 5.3. Predicted varicella incidence rates from 2005 to 2055 under a one-dose and 
two-dose vaccination strategy, by second dose coverage and age of administration of the 
second dose.  
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Figure 5.4.  Age specific seroprevalence curves at various times since the implementation 
of routine one-dose varicella vaccination.  These curves indicate past infection, either as a 
natural case or a breakthrough case.  The base values for all parameters and the base 
mixing matrix was used in these simulations, and there is no second dose. 
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Figure 5.5.  Percentage of each disease type by second dose coverage rate and year.  In 
vaccinated individuals, disease can be mild, or severe.  Severe breakthrough disease is 
similar to disease in unvaccinated individuals. 
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VI. A Systematic Method for Sensitivity Analysis of a Deterministic Model of 
Infectious Disease Transmission 
 
Steven Valeika, Alun L. Lloyd, and Annelies Van Rie 
 
A. Abstract 
A sensitivity analysis is used to determine the sensitivity of the model output to 
the values of input parameters, and model structure, and should be performed for all 
models of disease transmission. Simple techniques like univariate sensitivity analysis and 
best vs. worst-case scenario analyses overlook parameter interactions and non-linear 
relationships between parameters and outcome.  Probabilistic methods, such as Latin 
Hypercube Sampling are powerful and efficient, however they are associated with 
statistical assumptions that may not always be valid, and are not always tested.  In this 
study we present a simple, systematic method to perform sensitivity analysis of a 
deterministic mathematical model of infection transmission.  The methods can be used as 
a complete sensitivity analysis, or to investigate any possible violations of the 
assumptions of more complex probabilistic techniques. 
 
B. Introduction 
 Sensitivity (or uncertainty) analysis is a critical component in the analysis of 
models of infectious disease transmission as it allows modelers to assess how uncertainty 
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in the model’s structure, assumptions and parameter values affect the outcome. The 
choice of parameter values for the base case model is informed by estimates found in the 
literature, original data collection, or expert opinion.  Additionally, the range of 
parameter values from prior models may provide a starting point for parameter selection. 
 Uncertainty regarding a parameter’s value may relate to the mean value, its 
variance, or both.  Some parameters have a known mean and limited variance around the 
mean, making sensitivity or uncertainty analysis redundant except in specific situations 
such as outbreaks in small populations.  Other parameters may have a known mean and a 
known, but important variance. Incorporating this range in a model is important for 
generalizability of the results.  Other parameters may have a known mean but unknown 
variance (either in size or distribution).  When estimates from different studies vary 
widely, there is important uncertainty regarding both the mean and variance. Finally, for 
some parameters for which we do not have good estimates of the mean or variance.2 
There is no standard method to conduct sensitivity analyses in transmission 
modeling studies.  The simplest type of sensitivity analysis is univariate analysis, where 
one examines how changes in the values of a parameter change the value of the outcome, 
typically in relation to the output of a pre-defined, base model.  For a model with k 
parameters, k – 1 parameters are held at their baseline values, while a parameter of 
interest is varied.  This technique assumes that parameters are independent of each other, 
and that the values of other parameters are known with a relatively high degree of 
precision and certainty.3, 4   
In many modeling papers, modelers choose an a priori determined best and 
worst-case scenario for the values of model parameters, often based on expert opinion.  
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Using this approach, these models make an implicit assumption of a monotonic 
relationship between the parameter and outcome values. This assumption is problematic 
when modeling large, non-linear systems where single parameters may affect the 
outcome in a non-linear fashion, for example if there is a U-shaped relationship between 
the values of a parameter and the output.  
 Probabilistic methods, in which both a range and distribution of parameter values 
are assigned, and which use sampling techniques such as Latin hypercube sampling 
(LHS) or Monte Carlo methods, have become a popular method to assign input vectors.  
Random samples are drawn without replacement from parameter distributions, and these 
samples are used as input vectors into the model.  This method is powerful and efficient, 
especially for complex models with large numbers of parameters. A disadvantage of this 
method is that the distributional form for all of the parameters, which may not be known, 
must be specified.  Additionally, this method assumes that each parameter is 
monotonically associated with the outcome, and that the parameters are independent. 3 
Even though it is well known that biological and ecological systems have parameters that 
interact with each other, violating the assumption that parameter estimates are 
independent of each other, these assumptions often go unaddressed. 1 
 In this paper we apply a systematically performed sensitivity analysis of an age-
structured, deterministic, compartmental transmission model. This study concentrates on 
uncertainty in parameter values rather than in model structure.  A full-factorial analysis, 
where all possible parameter combinations are used, explores the entire k-dimensional 
parameter space. The input into a transmission model can be thought of as a vector of 
size k, where k is the number of parameters.  The number of possible vectors scales with 
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kN where N is the number of distinct parameter values.  This method can result in very 
large numbers of vectors that need to be inspected.  An advantage of this method is that 
no assumptions about the distributions of parameter values, or of interactions between 
parameters, is needed.3, 5 
We test the assumptions of LHS by determining if there are interactions between 
parameters, or if parameters have non-linear or non-monotonic relationships with the 
outcome. We define the parameters that correspond to the best and worst case scenarios 
based on the output of the full factorial sensitivity analysis, and compare these to the a 
priori determined best and worst-case scenarios.  Finally we assess how sensitivity 
analysis is outcome specific, parameters that appear important for one outcome may not 
affect the sensitivity of a related outcome.1 We demonstrate the value of this new 
approach to sensitivity analysis suing a published deterministic method of varicella 
transmission.  
 
C. Methods 
1. Model structure and parameters 
 The model has been described previously.  Briefly, it is a compartmental model 
where susceptible individuals can either become infected and permanently immune, 
successfully vaccinated and permanently immune, or vaccinated with an incomplete 
response, leading to infection (breakthrough case), and then permanently immune 
following recovery. Four parameters of interest for the sensitivity analysis are (1) the 
probability of a sub-optimal immune response to vaccination ϕ, which defines the 
proportion of vaccinees that move into a class of vaccinated but susceptible individuals; 
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(2) the susceptibility of vaccinated susceptibles relative to unvaccinated susceptibles, b; 
(3) the relative infectiousness of mild breakthrough cases, m; and (4) the rate that 
immunity to a first dose of vaccine wanes, ω.  We study three different outcomes, the 
cumulative number of cases in unvaccinated, cumulative number of breakthrough cases 
in vaccinated individuals, and the peak incidence rate during a post-vaccination epidemic. 
 
 2. Selection of base model parameters 
 The base values for these parameters were determined from an extensive review 
of the literature (table 6.1).  The sub-optimal response rate ϕ, sometimes referred to as the 
failure rate, is an example of a parameter where different estimates for the mean are 
found in the literature, introducing important uncertainty. In a large population based 
serosurvey which used the fluorescent antibody membrane antigen (FAMA) test, the gold 
standard for serologic testing for varicella antibodies, 76% (ϕ = 0.24) of vaccinated 
children were seropositive 6-weeks after vaccination, with values ranging from 67% 
(ϕ=0.33) to 87% (ϕ=0.13) depending on study site.6  Pre-licensure trials using the more 
widely available but less specific glycoprotein ELISA indicated that >95% (ϕ=0.05) of 
vaccinees had positive varicella titers.7-11 We therefore choose 0.25 as the base value for 
ϕ, with a range from 0.05 to 0.40  
 Values for the residual susceptibility of sub-optimal responders, b, and the 
relative infectiousness, m, are primarily taken from household contact studies.6, 9, 12 In a 
contact studies 77% of FAMA negative, unvaccinated individuals and 46% of FAMA 
negative vaccinated individuals (the vaccinated susceptibles or sub-optimal responders) 
became infected after contact with an unvaccinated case, corresponding to a residual 
 103 
susceptibility b, of 0.59.6, 9, 13 We used a value of 0.6 for this parameter, and assigned a 
range of 0.30 to 0.90.  
In a household contact study, breakthrough cases with mild disease (<50 lesions), 
were one-third as infectious as unvaccinated cases, and breakthrough cases with more 
severe disease were just as contagious as unvaccinated cases.12 Therefore we assign 0.33 
to the baseline value for m, the relative infectiousness of mild breakthrough cases.   
Given that our estimate comes from a single study, a wide range of values (0.2 to 0.8) is 
used in the sensitivity analysis. 
 The value for parameter ω, the waning rate of vaccine-induced immunity, is the 
most uncertain.  Studies performed prior to the routine implementation of VZV 
vaccination, i.e. at times of high levels of wild VZV circulation in the community, found 
humoral persistence for at least 10 years9, 20-22, in contrast several outbreak investigations, 
as well as data from an active surveillance site, documented increasing risk of 
breakthrough infection with increasing time since vaccination.23-28 We vary ω to give an 
average duration of full protection (1/ω) from 1 year to lifelong, and choose 30 years for 
the base case. 
 
3. Validation of base model parameters  
 To validate the choice of our base parameter values, the output from our base 
model is compared against data of the annual varicella incidence rates observed since 
1995, when the United States implemented routine single-dose vaccination of infants. 
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4. Sensitivity analysis 
 Using a full factorial analysis, the model was run using every parameter 
combination possible.  Each combination can be thought of as an input vector, with a 
single value for each parameter.  To create vectors, the continuous distribution of 
parameters was reduced to a series of discrete values close enough together as to not miss 
any possible departures from linearity in the relationship between the parameter and 
output.  For parameters distributed between 0 and 1, we added or subtracted 0.05 from 
the base value to the upper and lower values of the range.   
 First we perform univariate analysis, in which one parameter is varied from its 
base case while all other parameters are set to their base values, and display the results 
with spider plots. The relative change in the parameter from its base value is graphed 
against the relative change in the outcomes.  
Parameter interactions are analyzed using box plots.  The box plot displays all 
possible outcomes across different values of a single parameter. In the absence of 
interaction, the effect of any parameter on the outcome should be the same across the 
values of another parameter.  With one parameter held at a single value, variability that is 
observed in the outcomes is thus due to variability and interaction with other parameters.  
Next we assess the linearity of the relationship between each parameter and the 
outcome, independently of the other parameters, using the partial correlation coefficient.  
This statistic gives a value of -1 to 1, which represents complete inverse and positive 
linearity respectively, with 0 indicating a lack of a linear relationship.   This is a useful 
technique, but it assumes independent relationships amongst the parameters, unless 
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interaction terms are explicitly specified.  However, if there is no evidence of a linear 
relationship, this does not mean there is not some other type of relationship.29  
Then an analysis of extremes is undertaken.  Typically, “best” and “worst” case 
scenarios are determined a priori.  In our case, the worst-case vector would include the 
following parameter values: ϕ=0.4, b=0.9, m=0.8, and 1/ω=1 year, while the best case 
would use the opposite extremes: ϕ=0.05, b=0.3, m=0.2, and ω=0.  Examining only these 
extremes implicitly assumes a monotonic relationship between parameter values and the 
outcome.  If this assumption does not hold, due to non-linearity introduced by interaction 
between parameters, the true worst case could occur with vectors that would not a priori 
be thought of as a worst case.  The full factorial analysis is used to identify the vectors 
that rise to the actual best and worst case outcomes. 
Finally we examined the possibility that different but related outcomes may differ 
in their sensitivity to parameters in the model using scatter plot that graph the relationship 
between different outcomes.   
 
D. Results 
 The annual incidence rates, observed and model based, for the first 10 years of 
vaccination, before a second dose recommendation became standard, are shown in figure 
6.1.  The similarity between the observed annual incidence rates in the United States 
compared with the annual incidence rates generated with the base case model gives 
confidence for the future predictions of the model.  As we did not use the observed 
incidence rate data to specify our parameter values, the match between observed data and 
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model output was not pre-determined, and thus qualitatively validates the base model 
parameters. 
 Figure 6.2 shows the range of total number of cases (outcomes) generated by runs 
of the model using different parameter values.  A scatter plot (figure 6.3) compares the 
total number infected in the unvaccinated with the total number of breakthrough cases in 
vaccinated individuals.  While there is a general positive association (correlation 
coefficient 0.73) between unvaccinated and breakthrough cumulative incidence, there are 
situations where high numbers of unvaccinated cases are associated with low numbers of 
breakthrough cases and vice versa. 
 The spider plots in figures 6.4a and 6.4b explore the sensitivity of the model 
outcomes to changes in the relative infectiousness, m, of mild breakthrough cases.  In 
contrast to the positive linear relationship between m and the total number of cases 
(figure 6.4a), we did not find a linear relationship between m and the peak incidence rate 
(figure 6.4b), highlighting how the choice of the outcome of interest affects the results of 
the sensitivity analysis. 
Table 6.3 gives the partial correlation coefficients for the associations of the 
parameters with the number of unvaccinated and breakthrough cases, under a condition 
of 75% second dose coverage, quantifying the strength of a linear relationship with these 
outcomes.  Each of the four parameters displays moderate to strong linear relationships 
with number of breakthrough cases, but weak to moderate relationships with 
unvaccinated cases. These relationships quantify the linear effects that were seen in the 
spider plots. 
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Using box plots we found evidence of interaction between parameters.  The 
model was highly sensitive to the values of ω, and its sensitivity to all other parameters in 
the model was dependent upon the value of ω (figure 6.5).  This is evidenced by the 
decreasing amount of variability in the outcome values as 1/ω increases.  For example, 
the model is insensitive to changes in b when ω is low, but very sensitive to b when ω is 
high (figure 6.6). 
 Based on the a priori determined best and worst-case scenarios, the predicted 
minimum and maximum number of cases during the course of the epidemic is 787,423 
and 1,445,730 respectively for unvaccinated cases, and 47,810 and 5,975,570 
respectively for breakthrough cases.  The actual best and worst-case outcome, as 
predicted by the full-factorial sensitivity analysis was 787,423 and 1,590,960 respectively 
for unvaccinated cases, and 47,810 and 5,975,570 respectively for breakthrough cases 
(table 6.2). The actual parameter vector associated with the highest number of 
unvaccinated cases is: ϕ=0.05, b=0.4, m=0.8, and 1/ω=1, rather than our a priori 
determined worst vector of: ϕ=0.40, b=0.90, m=0.80, 1/ω=1 year.  The a priori best-case 
vector: ϕ=0.05, b=0.30, m=0.20, 1/ω = 100 years, matched the actual lowest number of 
unvaccinated and breakthrough cases.  The a priori worst-case vector predicted the actual 
number of maximum breakthrough cases.  
 
E. Discussion 
 This study developed a step-by-step method for examining the sensitivity of 
various model outputs to the input parameters using a full-factorial analysis.  This method 
uses all possible parameter values and does not require knowledge of parameter 
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distributions or assumptions regarding monotonicity between parameters and outcomes 
or assumptions about interactions between parameters.  Graphical methods convey an 
instant understanding of relationships between variables.  Quantitative techniques 
confirm conclusions drawn from graphical data. It synthesizes methods from the 
economic and risk analysis literature and methods currently used by some infection 
modelers and thus presents the most cohesive strategy for uncertainty analysis in 
infectious disease modeling studies.   
Using this approach, we were able to define the range of outcomes and their 
frequency, determine which parameters the model was most sensitive to, identify 
parameter interactions, assess the assumptions needed for LHS, and examine how to 
check that the a priori best and worst-case scenario matches the actual lowest and highest 
number of cases.  
Quantitative results for the linear relationship between the parameters and 
outcomes can be modeled using partial correlation coefficients (table 6.4).  In our case, 
the partial correlation coefficients did not give much additional information over our 
graphical analysis.   
We used box plots to convey information about the multivariate effects of 
parameters.  In figure 6.6, there is a large increase in the variability of the total number of 
cases at high values of ω, and very little variability at lower values.  This is evidence of 
interaction between ω and one or more parameters in the model.  Other parameters have 
different effects on the outcome at different values ω, indicating that the linear changes 
displayed in the spider plots may not hold when multiple parameters are varied from the 
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base value.  Such an interaction is shown between ω and b in figure 6.7.  At low values of 
ω, b has very little effect, however as ω increases, the effect of b becomes greater.   
We also demonstrated that the choice of outcome that is analyzed could lead to 
different conclusions about the sensitivity of the model to certain parameters (figures 6.4a 
vs. 6.4b).  For example, we found a positive linear relationship between m and the 
number of infections in both vaccinated and unvaccinated individuals, but no linear 
relationship with the peak, post-vaccination incidence rates under a one-dose vaccine 
strategy.  These disparate results seem to indicate some problem in the model.  However, 
with increased infectiousness, breakthrough cases will give rise to a slow increase in 
breakthrough and unvaccinated incidence rates over time, resulting in fewer vaccinated 
and unvaccinated susceptibles available to trigger a large epidemic, providing a rational 
explanation for the seemingly counter-intuitive result.  
Analysis of best and worst case scenarios are often helpful for communicating the 
results of models to policy makers and health economists.  In this model, the a priori 
choices for best and worst case parameter combinations produced numbers of infections 
that were very close to the best and worst-case outcomes as determined using the full-
factorial analysis.  This technique is valuable in that it demonstrates the presence or 
absence of a monotonic relationship between the parameters and the output, and displays 
whether it is appropriate to consider the a priori identified best and worst case input 
vectors. The actual maximum number of unvaccinated cases arose from a different vector 
than our pre-determined worst-case vector.  The source of the discrepancy is unclear. The 
parameters had stronger relationships with breakthrough infection.  The exact match for 
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the observed and a priori expected number of cases for the other values is good evidence 
that the relationship between the parameters and the outcome is monotonic. 
In conclusion, we were able to assess the relationships between the parameters 
and the outcomes of interest, and the relationships between parameters. The techniques 
we describe are easy to perform for relatively simple models with a limited number of 
parameters, and are amenable to intuitive interpretations based on graphical analysis. A 
full-factorial analysis does not rely on assumptions about the independence of parameters 
or the linearity of relationships between the parameters and the outcomes. In this sense 
this method is valuable and should be used before more complex probabilistic techniques 
such as LHS, which require more assumptions, are used.  If it is shown that those 
assumptions are not violated, then probabilistic methods like LHS can be used with 
confidence.  Using this technique we were also able to confirm the appropriateness of 
pre-determined best and worst-case scenarios, as well as demonstrate that important 
interactions existed between some parameters.  This type of information is invaluable 
when assessing the validity and plausibility of transmission models, and makes the 
techniques of the sensitivity analysis clear. 
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Table 6.1. Base parameter values and range used in sensitivity analysis. 
Parameter Base Value Range Description 
ϕ 0.25 0.05 – 0.4  Sub-Optimal Response 
Rate 
b 0.6 0.3 – 0.9  Residual susceptibility 
of vaccinated 
susceptibles 
m 0.33 
 
0.2 – 0.8  Reduced infectiousness 
of mild breakthrough 
cases 
ω 0.0333/y 
(30 Year 
Duration) 
1 to 100 year duration  Waning of vaccine 
induced immunity 
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Figure 6.1. Model Predicted Incidence (Dashed) and Observed Incidence (Solid) from 
1994 to 2006.  Both curves are scaled relative to their 1994 rates to facilitate 
comparisons. 
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Figure 6.2. Distribution of the Post-Vaccination Total Number of Cases 
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Figure 6.3.  Relationship between number of unvaccinated cases and number of 
breakthrough cases. 
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Figure 6.4a 
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Figure 6.4b. 
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Figure 6.4.  Changes in the relative infectiousness of mild breakthrough cases are relative 
to its base value of 0.33, changes in the number of infections predicted are relative to the 
number of infections predicted with the base case model (6.4a), and changes in the peak 
post-vaccine incidence rates are relative to the base case peak incidence rate(6.4b).  
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Figure 6.5.  Box plots summarizing the values for the total number of cases the duration 
of immunity in years, 1/ω.  The box is the interquartile range, the line within the box is 
the median, the whiskers represent the range for most values, and the dots are outliers. 
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Figure 6.6.  Relationship between number of cases and b, the residual susceptibility of 
sub-optimal responders over different levels of the waning rate, ω. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 119 
Table 6.2. The model observed, and a priori predicted maximum and minimum number 
of cases over the course of the outbreak.  These simulations used a single dose 
vaccination strategy, and the base mixing matrix. 
 Unvaccinated Breakthrough 
 Maximum Minimum Maximum Minimum 
Observed 1,590,960a 787,423 5,975,570 47,810 
a priori predicted 1,445,730 787,423 5,975,570 47,810 
 
a The parameter vector that produced the actual maximum number of cases in the 
unvaccinated was ϕ=0.05, b=0.4, m=0.8, and 1/ω=1. 
 
 
 
 
 
Table 6.3.  Partial correlation coefficients of the relationship of the parameters with the 
number infected with 75% second dose coverage. Do one dose strategy! (check on IR vs. 
Cumulative) 
    Outcome 
Parameter Unvaccinated Breakthrough 
ϕ -0.0461 0.1382 
b 0.0618 0.7032 
m 0.1714 0.3017 
ω -0.0845 0.6004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 120 
F. References 
 
1. Walker D, F. Allowing for uncertainty in economic evaluations: Qualitative sensitivity 
analysis. Health Policy and Planning 16, 435-443 (2001). 
 
2. Briggs, A., Sculpher, M. & Buxton, M. Uncertainty in the economic evaluation of 
health care technologies: the role of sensitivity analysis. Health Econ. 3, 95-104 (1994). 
 
3. Blower & Dowlatabadi. Sensitivity and Uncertainty Analysis of Complex Models of 
Disease Transmission: An HIV Model, as an Example. International Statistical Review 
62, 229 (1994). 
 
4. Briggs, A. & Sculpher, M. Sensitivity analysis in economic evaluation: a review of 
published studies. Health Econ. 4, 355-371 (1995). 
 
5. Briggs, A. H. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 
17, 479-500 (2000). 
 
6. Michalik, D. E. et al. Primary vaccine failure after 1 dose of varicella vaccine in 
healthy children. J. Infect. Dis. 197, 944-949 (2008). 
 
7. Li, S. et al. Inverse relationship between six week postvaccination varicella antibody 
response to vaccine and likelihood of long term breakthrough infection. Pediatr. Infect. 
Dis. J. 21, 337-342 (2002). 
 
8. Lieberman, J. M. et al. The safety and immunogenicity of a quadrivalent measles, 
mumps, rubella and varicella vaccine in healthy children: a study of manufacturing 
consistency and persistence of antibody. Pediatr. Infect. Dis. J. 25, 615-622 (2006). 
 
9. Ampofo, K. et al. Persistence of immunity to live attenuated varicella vaccine in 
healthy adults. Clin. Infect. Dis. 34, 774-779 (2002). 
 
10. Johnson, C. E., Stancin, T., Fattlar, D., Rome, L. P. & Kumar, M. L. A long-term 
prospective study of varicella vaccine in healthy children. Pediatrics 100, 761-766 
(1997). 
 
11. White, C. J. et al. Modified cases of chickenpox after varicella vaccination: 
correlation of protection with antibody response. Pediatr. Infect. Dis. J. 11, 19-23 (1992). 
 
12. Seward, J., Zhang, J., Maupin, T., Mascola, L. & Jumaan, A. Contagiousness of 
varicella in vaccinated cases: a household contact study. JAMA 292, 704-8 (2004). 
 
13. LaRussa, P., Steinberg, S. P., Seeman, M. D. & Gershon, A. A. Determination of 
immunity to varicella-zoster virus by means of an intradermal skin test. J. Infect. Dis. 
152, 869-875 (1985). 
 
 121 
14. Halloran, M. Epidemiologic effects of varicella vaccination. Infect. Dis. Clin. North 
Am. 10, 631-55 (1996). 
 
15. Balfour, H. H.,Jr et al. Acyclovir treatment of varicella in otherwise healthy children. 
J. Pediatr. 116, 633-639 (1990). 
 
16. White, C. J. et al. Varicella vaccine (VARIVAX) in healthy children and adolescents: 
results from clinical trials, 1987 to 1989. Pediatrics 87, 604-610 (1991). 
 
17. Brisson, M., Edmunds, W., Gay, N., Law, B. & De Serres, G. Analysis of varicella 
vaccine breakthrough rates: implications for the effectiveness of immunisation 
programmes. Vaccine 18, 2775-8 (2000). 
 
18. Brisson, M., Edmunds, W., Gay, N., Law, B. & De Serres, G. Modelling the impact 
of immunization on the epidemiology of varicella zoster virus. Epidemiol. Infect. 125, 
651-69 (2000). 
 
19. Lenne, X. et al. Economic evaluation of varicella vaccination in Spain: results from a 
dynamic model. Vaccine 24, 6980-9 (2006). 
 
20. Kuter, B. J. et al. Oka/Merck varicella vaccine in healthy children: final report of a 2-
year efficacy study and 7-year follow-up studies. Vaccine 9, 643-647 (1991). 
 
21. Silber, J. L., Chan, I. S., Wang, W. W., Matthews, H. & Kuter, B. J. Immunogenicity 
of Oka/Merck varicella vaccine in children vaccinated at 12-14 months of age versus 15-
23 months of age. Pediatr. Infect. Dis. J. 26, 572-576 (2007). 
 
22. Vessey, S. et al. Childhood vaccination against varicella: persistence of antibody, 
duration of protection, and vaccine efficacy. J. Pediatr. 139, 297-304 (2001). 
 
23. Chaves, S. et al. Loss of vaccine-induced immunity to varicella over time. N. Engl. J. 
Med. 356, 1121-9 (2007). 
 
24. Chaves, S. S. et al. Varicella disease among vaccinated persons: clinical and 
epidemiological characteristics, 1997-2005. J. Infect. Dis. 197 Suppl 2, S127-31 (2008). 
 
25. Galil, K. et al. Outbreak of varicella at a day-care center despite vaccination. N. Engl. 
J. Med. 347, 1909-1915 (2002). 
 
26. Grose, C. Varicella vaccination of children in the United States: assessment after the 
first decade 1995-2005. J. Clin. Virol. 33, 89-8 (2005). 
 
27. Vazquez, M. et al. Effectiveness over time of varicella vaccine. JAMA 291, 851-5 
(2004). 
 122 
 
28. Haddad, M. et al. Vaccine effectiveness during a varicella outbreak among 
schoolchildren: Utah, 2002-2003. Pediatrics 115, 1488-93 (2005). 
29. Iman, Helton & Campbell. An approach to sensitivity analysis of computer models: 
Part II - Ranking of input variables, response surface validation, distribution of effect and 
technique synopsis. Journal of Quality Technology 13, 232 (1981b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VII. Discussion and Conclusions 
 This dissertation is the first study to model the effect of a two-dose varicella 
vaccination regime.  It expands on other models, not only by analyzing the effect of a 
second dose, but also in its more detailed structure and parameterization recognizing the 
most recent data.  It provides information about the near term epidemiology of varicella, 
the long-term epidemiology, and the changes in the average ages of infection compared 
with the pre-vaccination, and one-dose vaccination eras.   
 Our model contributes to the understanding and expectations of the effect of both 
one and two dose vaccination for varicella in the following ways. 1) It uses the most 
specific estimate of the relative infectiousness of breakthrough cases, 2) it accounts for 
mild and severe breakthrough disease, and identifying their contribution to the 
epidemiology of varicella, 3) provides data-driven estimate for the residual susceptibility 
of vaccinees with a poor response to vaccination, 4) and recognizes the importance of a 
sub-optimal immune response as a driving force behind breakthrough infection, 
demonstrating how the vaccine effectiveness in the field is less than that predicted by pre-
licensure efficacy studies, 5) it predicts that the United States is on the cusp of a large, 
post-vaccination resurgent epidemic, 6) it examines the impact of a two-dose vaccination 
regimen, 7) compares different age recommendations for giving the second dose of 
vaccine, and 8) provides the most thorough sensitivity analysis of a varicella model to 
date. 
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The sensitivity analysis determines the parameters with the most associated 
uncertainty.  It also is the first study to present a systematic, step-by-step, qualitative 
technique for sensitivity analysis in infection modeling studies.  It synthesizes methods 
from the economic and risk analysis literature, and methods currently used by some 
infection modelers, to present the most cohesive strategy for uncertainty analysis in 
modeling studies.  Additionally, it incorporates simple methods that have not been used 
previously that can be used to address interactions between parameters, and to perform 
multivariate techniques.  This strategy can stand alone, but it is also a valuable 
complementary method to other techniques. 
 
A. Predicted epidemiology of varicella with different vaccination strategies 
 This study predicts that the resurgence in varicella incidence that began in 2003 
will continue through 2015.  The resurgence is a result of a buildup of susceptibles (S) 
protected by herd-immunity, as well as a buildup of partially susceptible vaccinated 
individuals (VS) as immunity either wanes or sub-optimal responses fail to be boosted as 
VZV circulation decreases.  The magnitude of the resurgent peak is striking, with 
incidence rates approaching pre-vaccination rates.  While this seems unrealistic at first 
glance, such peaks have been observed in post-vaccination measles epidemics as well as 
by other models of varicella transmission.1, 2 
 A two dose campaign will result in markedly lower incidence in the long term, 
even at modest (50%) second dose coverage rates, but will only minimally attenuate the 
size of the short-term resurgence.  Concern over the timing of the second dose has been 
expressed due to the possibility of breakthrough infection occurring in pre-schoolers who 
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had a suboptimal response to the first dose of vaccine.3 However, our results indicate that 
giving the second dose at age 2 rather than at age 5 will result in a higher peak incidence 
in the next 15 years. Giving the second dose at 5 years may reduce the number of 
susceptibles at school entry, a time when mixing rates increase dramatically.  In the long-
term, receiving a second dose at 2 vs. 5 years makes little difference.   
 
B. Severity of disease and age of infection 
 Over time, mild breakthrough varicella will predominate.  Second dose coverage 
rates and age at vaccination does not appreciably alter the relative proportions of disease 
caused by natural, severe breakthrough, or mild breakthrough illness.  The age 
distribution of varicella incidence will also change over time.  This is a well-studied 
effect of any vaccination campaign.4-6 Currently, the highest incidence rates are seen 
between 10 and 14 years of age.  As the average age of infection increases, a higher 
proportion of varicella infections will occur in the 15 to 25 year old age group, raising 
concern over the incidence of congenital varicella. Such perverse effects of vaccination 
are well known for rubella.7 However, as the majority of these cases will have mild 
breakthrough disease they may not suffer the severe adverse effects of natural infection 
seen in older age groups.  It is also unknown how the fetus is affected by breakthrough 
varicella relative to natural disease. 
 
C. New estimates for important parameters 
 The base values for the model parameters were determined from an extensive 
review of the literature.  The sub-optimal response rate ϕ is an example of a parameter 
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where different estimates for the mean are found in the literature, introducing important 
uncertainty.   
We were able to utilize a recent review of studies where sub-optimal response to 
vaccination was confirmed with a lack of humoral response documented by the FAMA 
test.  The attack rate in sub-optimal responders vs. the attack rate in completely 
susceptible, unvaccinated individuals provides the first use of a data-driven value for this 
parameter in a varicella modeling study. 8, 12, 13 
 Breakthrough cases were previously considered half as infectious as unvaccinated 
cases.2, 14, 15 However, this value is the average infectiousness of both mild and severe 
breakthrough cases.  We used data from a household contagiousness study that 
determined the infectious of mild vs. severe breakthrough cases.  This allowed us to 
specifically model mild and severe cases, and use a more specific estimate of m for mild 
breakthrough cases alone.  This is an advantage when considering the long-term 
epidemiology of varicella.  Since mild cases are expected to increase relative to severe 
and natural cases, the use of a single measure of infectiousness for all breakthrough cases 
will be overestimate the true infectiousness of these cases.11 
The base case was validated qualitatively by comparing the observed varicella 
incidence from 1995 to 2005 with the model predicted incidence over the same time 
period.  The model was not fit to those previously observed data, thus the similar patterns 
between our model and the data reflect the suitability of our parameter choices. 
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 D. Insights from the sensitivity analysis 
 1. Parameter uncertainty 
With univariate analysis, we were able to show that the cumulative incidence of 
breakthrough infection had a modest linear relationship with the sub-optimal response 
probability, ϕ, and incidence in the unvaccinated was almost completely insensitive to 
different values of ϕ.  The residual susceptibility of vaccinated susceptibles, b, had a 
strong linear relationship with breakthrough infection, and a weaker linear relationship 
with infection in unvaccinated individuals.  Increases in the infectiousness of 
breakthrough cases, m, was positively associated with both the number of breakthrough 
infections and infections in unvaccinated.  
We show that the parameter with the greatest uncertainty, the waning rate of first 
dose immunity ω, was also the parameter that the output of the model was most sensitive 
to.  This combination of high uncertainty with high sensitivity indicates a great need for 
better estimates for ω in order to have precise results from transmission models.  
We demonstrated how the choice of outcome that is analyzed could lead to different 
conclusions about the effect of some parameters.  We showed a positive relationship 
between m and the number of infections in both vaccinated and unvaccinated individuals.  
If the peak incidence rate during the post-vaccination resurgent epidemic were used as 
our outcome instead, our conclusion regarding m would have been that increasing the 
infectiousness of breakthrough cases decreases the impact of the epidemic, and has an 
inverse relationship with total, unvaccinated, and breakthrough incidence rates.  This 
could lead to opposite conclusions about the effect of this parameter.  This highlighted 
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the importance of understanding what outcomes are measured when assessing the effect 
of a parameter, especially when values from one study are applied to another. 
Multivariate analysis, visualized with box plots, revealed interactions between ω 
and all of the other parameters.  The evidence for this is the change in the variation in 
outcome values across different values of ω.  When ω is held at a single value, the 
variation in outcome measures is related to the sensitivity of the model to other 
parameters in the model.  There was relatively little variation in the value of the 
cumulative incidence at low values of ω.  At such values, the model is less sensitive to 
the values of other parameters in the model.   
We showed direct evidence of the interaction of ω and b, the relative 
susceptibility of vaccinated susceptibles.  At high values of ω, there was no linear 
relationship between b and the outcome.  However, at higher values for ω, the model 
outcome was quite sensitive to b.  Similar interactions were found between ω and ϕ.  
Thus, the modest linear effect seen between ϕ and the outcome in the univariate analysis 
was partially due to the strong effect of ω; at high values for ω, there was a stronger 
linear relationship between ϕ and the total number of infections. 
 
 2. Sensitivity analysis methodology 
We demonstrated the synergy associated with the comparison of multiple methods 
of sensitivity analysis vs. just choosing a single method.  A highlight of our sensitivity 
analysis is its simplicity.  Calculating precise statistics in the sensitivity analysis is not 
helpful if precise predictions were not a goal of the original transmission model.  Thus, 
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graphical techniques, which can be qualitative in nature while conveying an instant 
understanding of parameter-outcome relationships is ideal.   
We used a full-factorial analysis to identify every possible output of the 
transmission model with every possible combination of input parameter values.16-19 No 
assumptions are required about the distributional form that the values for each parameter 
follow, nor are there assumptions of independence among parameters.  In fact, our 
method makes it easy to highlight when such interactions occur.  The ability of the 
analysis to uncover interactions between parameters so simply, and without any statistical 
assumptions, is a highlight of our sensitivity and uncertainty analysis methods.  Our 
method should be a first step before performing other types of sensitivity analysis.  It can 
validate the appropriateness of the commonly used best and worst-case scenario analysis, 
and highlight violations in the assumptions that could make probabilistic techniques 
problematic.  
 
E. Strengths and Limitations 
 1. Varicella transmission study 
There are several limitations to this study.  Uncertainty remains about parameter 
values, model structure and assumptions.  The output of this model was highly sensitive 
to the duration of immunity, which is also the parameter estimated with the least amount 
of certainty. Another problem is our reliance on possibly non-precise estimates for 
contact and transmission rates within and between age groups, especially in the older age 
groups. Mixing matrices are determined by the pre-vaccination age specific changes in 
incidence.  Since most older children and adults have experienced past infection, there is 
 130 
very little change in the seroprevalence with age, and determination of their contact rates 
become problematic.  To compound this problem, vaccination increases the average age 
of infection, increasing the epidemiologic importance of these older age groups.  Thus 
there is uncertainty about the accuracy of the long-term predictions of this model, causing 
our confidence in the results to decrease as time increases.4, 5, 20, 21 
The timing of events that we predict may also lack some precision.  We show a 
remarkable fit between our model predicted incidence and the actual observed incidence 
between 1995 and 2005, but the results from our model trails the observed outcomes in 
the early part of the simulation.  This lag is likely due to the catch-up vaccination 
program that was aimed at older susceptible children and adults who had not had 
varicella, and who were not vaccinated as children.  Our model did not include such 
catch-up vaccination, as the estimates for its coverage rates were not precisely estimated, 
and under different assumptions of catch-up rates, our simulations showed little 
difference in the long-term epidemiology of varicella. 
Another limitation in our model is that we do not account for immigration into the 
system.  Currently the United States is the only country with routine varicella 
vaccination.  Thus imported cases will contribute to the maintenance of infection in the 
population, and possibly lead to outbreaks in certain situations.   
In spite of these uncertainties, the general qualitative predictions of this model are 
likely to hold true, especially in the short-term.  We have the benefit of more than 10 
years of incidence data collected since universal vaccination started.  This enabled us to 
validate our model in ways that earlier models were unable to do.  The predictions of the 
model for the years 1995 to 2006 are highly consistent with what has been observed in 
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terms of incidence rates, seroprevalence, and an increasing burden in older age groups.  
Additionally, the consistency was only seen with the base matrix and matrix 1, which 
allowed us to eliminate several other estimates of contact patterns. 
The purpose of this model was to highlight expected trends in varicella incidence 
over time.  Thus we can confidently state that a continued resurgence of varicella 
incidence is expected for the next 10 to 15 years.  This resurgence is attenuated by, but 
not prevented by the new two-dose strategy. 
The public health impact of this resurgence is important.  The varicella vaccine is 
already refused more than any other mandatory childhood vaccine in the United States.22, 
23 Outbreaks are expected to continue in highly vaccinated populations, especially in 
school and day-care settings.  This will fuel the belief that the vaccine is not beneficial.  
However we show that the recommended two-dose strategy will be successful in 
eventually decreasing the incidence of varicella.  Even low coverage levels for the second 
dose will greatly reduce the incidence of varicella. 
 
2. Sensitivity Analysis 
We were constrained in our sensitivity analysis by the number of parameter 
vectors we could analyze.  Highly complex models with many parameters are not 
amenable to the full-factorial design.  While multivariate analysis techniques such as the 
box plot will still reveal the presence of interactions between parameters, it gets difficult 
to figure out which specific parameters are interacting. Such complex models are better 
served by probabilistic methods of sensitivity analysis, as long as the assumptions of 
those methods hold.   
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The methods we describe allowed us to confidently assess the relationships 
between the parameters and the outcomes of interest, and the relationships between the 
parameters themselves. The full-factorial analysis design does not require assumptions 
about the relationships between parameters and the outcome, and between parameters 
like probabilistic methods do.  The full-factorial design is thus ideal when there is 
uncertainty about the distributions for the values of the parameters, and when non-
monotonic relationships may be present between the parameters and the outcome.  This 
method tests the assumptions that underlie best and worst-case scenario analysis and 
probabilistic analysis methods.  Our techniques will help transmission modelers perform 
more valid sensitivity analyses, however it will also give consumers of transmission 
models, for instance policy makers or economists, a simply tool to evaluate the results of 
the model.  
 
F. Conclusions 
 This study predicts an important public health event looming as a post-
honeymoon outbreak of varicella is expected.  Other models also show an imminent 
resurgence, but our model, which has the most current parameter and model structure 
estimates, predicts that the outbreak will be large, under some scenarios approaching pre-
vaccination incidence rates.2 We also show that the current two-dose recommendation 
will make little difference in the magnitude of the upcoming epidemic.  However, we are 
the first to give estimates for the expected epidemiologic effects of the two-dose 
recommendation, and find that it is highly beneficial in the long term, even with generally 
low coverage as compared with first dose coverage. 
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 Our sensitivity analysis confirms the robustness of our model to the changes in 
some parameter values, and predicts an epidemic under most scenarios.  We were also 
able to identify the parameter the model was most sensitive to is the waning rate of first 
dose vaccination, ω.  This happens to be the parameter that has the most uncertain 
estimates of its value.  Thus the need for precise estimates of this parameter is 
highlighted.  We are also the first to present a step-by-step method for qualitative, 
deterministic sensitivity analysis of transmission models.  Since many transmission 
models are designed to give qualitative predictions, such a simple and qualitative analysis 
could be an important tool for future transmission modeling studies.  Additionally, our 
methods are a helpful complement to methods that aim to be more quantitative, such as 
Latin Hypercube Sampling. 
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